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ABSTRACT

Synthesis and Evaluation of Densely-Functionalized Troponoids
by
Danielle R. Hirsch
Advisor: Ryan P. Murelli

Herein, we document our efforts to expand the scope of troponoid synthetic methodology
towards densely-substituted scaffolds. This body of work has focused primarily on an
oxidopyrylium cycloaddition/ring-opening strategy for the synthesis and biochemical evaluation
of troponoids for assistance in a variety of medicinal chemistry studies. In Chapter 1, we outline
the use of this synthetic strategy in the profiling of a library of synthetic αHTs against an
aminoglycoside

antibiotic

resistance

enzyme

known

as

aminoglycoside-2’’-O-

nucleotidyltransferase [ANT(2’’)-Ia]. Enzymatic mechanistic insights have been gleaned from an
assessment of troponoid/antibiotic synergistic potential. In particular, two synthetic constructs
were identified as promising antibiotic adjuvant candidates, demonstrating a capacity to rescue
gentamicin activity while in the presence of ANT(2’’)-Ia-expressing bacteria. These results
validate the oxidopyrylium cycloaddition/ring-opening method as a viable approach to generating
new ANT(2’’)-Ia inhibitors, and provide some preliminary insight into the structural changes
required for effective inhibition.
In Chapter 2, we report the expansion of this synthetic strategy to a class of molecules
called 3,7-dihydroxytropolones, which have been indicated as promising leads in the development
of antiviral, antimelanoma and antimalarial agents. These synthetic developments were applied in
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the synthesis of a prospective biosynthetic precursor to the natural products puberulic and
puberulonic acid. Additionally, several new synthetic 3,7-dihydroxytropolones were identified as
promising scaffolds for anti-HSV drug development. This synthetic work was further expanded
towards additional investigations on the synthesis and physical evaluation of atropisomeric
troponoids, as discussed in Chapters 3 and 4. The research described within these chapters aims to
broaden our understanding of the physical properties of troponoids by using DFT and experimental
techniques to assess the rotational barriers of a series of benzenoid and troponoid scaffolds, as well
as by studying the atropselective bromination of a methoxytropolone. During the course of these
studies, 1H- and 13C-NMR experiments unveiled several mechanistic findings pertinent to future
development of the reaction.
Collectively, the studies described in this thesis aim to broaden our understanding of the
physical and biological properties of troponoids.
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Chapter I
Synthesis and Biological Activity of α-Hydroxytropolones
1.1 Introduction to α-Hydroxytropolones
α-Hydroxytropolones (αHTs) are a subset of the troponoid family of natural products1 that
possess therapeutic potential against a wide variety of disease targets.2 Structurally, the
molecules represent non-benzenoid aromatic ring scaffolds with a contiguous array of three
oxygen atoms (1.1a, αHTs) or four oxygens (1.1b, 3,7-dihydroxytropones [3,7-dHTs], vide
infra). Under certain basic conditions, αHTs can adopt a dianionic form, which is capable of
delocalizing charge throughout the molecule resulting in a trident-like assemblage of negatively
charged oxygen atoms (Figure 1.1).3 This makes them exceptional inhibitors of dinuclear
metalloenzymes.2,4 Studies on natural products β-thujaplicinol 1.2 and manicol 1.3 have
demonstrated that αHTs can exhibit potent activity against hepatitis B virus (HBV),5 human
immunodeficiency virus (HIV),6 herpes simplex virus 1 and 2 (HSV-1 and -2),7 and an
aminoglycoside resistance enzyme, ANT(2’’)-Ia.8

1.2. Synthetic Routes Towards α-Hydroxytropolones
Synthetic routes towards αHTs have historically focused on a variety of strategies
summarized in Scheme 1.1.

One of the earliest reports of troponoid total synthesis was
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published in 1960. Nozoe and coworkers were able to synthesize 3,7-dHT natural product
puberulonic acid 1.6 via a series of brominations and hydolyzations on purpurogallin 1.4
(Scheme 1.1A).9 While this is an effective method of generating hydroxylated tropones, it
suffers from a low yielding first step. Additionally, this oxidation-driven approach starts with the
full structural framework on purpurogallin and no new carbon-carbon bonds are formed – as
such, it does not lend itself well to generating diverse substitution patterns.

Around the same time, a cyclopropanation/ring-opening approach was developed by
Johnson and coworkers that addressed several of these limitations (Scheme 1.1B).
1,2,3-Trimethoxybenzene 1.7 was treated with ethyldiazoacetate and subsequently underwent a
6π-electrocyclic ring-opening followed by hydrolysis and oxidation to generate 3,7-dHT natural
product puberulic acid.10a-c Along the same lines, Balci and coworkers more recently were able
to generate αHT 1.12 via a cyclopropanation/6π-electrocyclic ring-opening on benzenoid 1.10
followed by a singlet oxygen-mediated rearrangement of 1.11 (Scheme 1.1C).10d
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In contrast to these cyclopropanation approaches which are followed by 6π-electrocyclic
ring-openings, Banwell and coworkers developed a strategy leveraging cyclopropanated
intermediates in Grob fragmentations for the generation of troponoid natural products
β-thujaplicinol 1.211 (Scheme 1.1D) and puberulic acid 1.912 (vide infra). A notable advantage
provided by this approach is the accessibility of bromotroponoid intermediates stemming from
1.14, which can be functionalized through cross-coupling11 and demethylated to generate
αHTs.13 An additional cyclopropanation approach was utilized several years later by Davies and
coworkers towards dimethoxytropolones 1.17.10e While not applied directly to αHTs, this method
granted quick access (only four steps from vinyl diazo carbonyl 1.15) to intermediates that are a
simple demethylation away from αHTs (Scheme 1.1E).
More recently, a cycloaddition/ring-opening approach was reported by Föhlisch and
coworkers (Scheme 1.1F).14 Starting with substituted furans 1.18 and pentachloroacetone,
8-oxabicyclo[3.2.1]octenes 1.19 were generated via a cycloaddition. These modifiable
intermediates were subsequently treated to a base-mediated ring-opening followed by
demethylation to provide αHTs 1.20, including β-thujaplicinol 1.2.

1.3. Previous Synthetic Chemistry-Driven Biological Studies on α-Hydroxytropolones
Despite the scope of studied synthetic approaches to αHTs as well as their promising
therapeutic potential, there has existed a surprising lack of SAR-amenable general synthetic
routes to access them.2 Fortunately, bioactive natural products can provide a suitable starting
point for synthetic derivatization, as was demonstrated by Le Grice and coworkers.6e In this
work, the alkene moiety of natural product manicol (1.3, Figure 1.2) was functionalized via
epoxidations, aminations, and dihydroxylations for an SAR study on HIV RT RNase H.
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While none of the 13 new αHT constructs exhibited significant advantages over the natural
product lead in enzymatic assays, all were active. More importantly, unlike manicol, some of the
analogs were capable of inhibiting viral replication in cell-based assays. Furthermore, many of
the analogs were also significantly less cytotoxic than manicol. This study demonstrates the
importance of synthesis in medicinal chemistry studies.
In a similar vein, Piettre and coworkers were able to synthesize a series of arylated
3,7-dihydroxytropolones by modifying an existing troponoid.15 This synthetic work was utilized
in SAR studies on inhibition of inositol monophosphatase (IMPase), an enzyme implicated in
bipolar disorder and manic depression. They were able to generate compounds 1.24 and 1.25 in a
4.7:1 ratio (Scheme 1.2). These compounds were then protected with methyl groups using
diazomethane, subjected to Suzuki cross-couplings using a variety of arylboronic acids, and
subsequently deprotected with TMSI/MeCN. While they were able to synthesize 37 new
dihydroxytropolones and subsequently screen them for their inhibitory activity against IMPase,
their best molecule tested had only a slight increase in potency over the parent compound.
Marquet and coworkers followed a similar oxidation/cross-coupling method to synthesize
arylated dihydroxytropolone analogs in an effort to develop broad activity HIV retroviral
hydroxytropolones.6b They were able to generate compounds 1.24 and 1.25 and carry them
4

through the subsequent Suzuki cross-coupling to generate a series of dihydroxytropolones
1.26a-c, which lead to some improved analogs against specific antiretroviral enzymes (Scheme
1.2). However, none of them were reported to have improved HIV replication activity over the
parent compound, and all proved to be inactive in an HIV-1 cellular assay. Synthetically, the
method is limited in that the initial bromination only goes to 57% conversion and gives a mixture
of products.

De novo synthetic methods offer opportunity to gain access to a more structurally diverse
group of molecules. One additional approach was developed by Banwell and coworkers, who
were able to accomplish late-stage introduction of substitution on αHTs.16 This method was used
to synthesize natural products β-thujaplicinol (vide supra)11 and puberulic acid (Scheme 1.3).12

While this method provides a route to modifiable late-stage synthetic intermediates and is viable
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from a structure-function standpoint, it is problematic in practice. The synthesis is long (10 steps)
and only allows access to one position on the αHT ring.

1.4. Murelli Synthesis and Antiviral Assessment of αHTs
As a method of overcoming these limitations, earlier work done in our lab based on
established [5C + 2C] cycloadditions17 showed that 8-oxabicyclo[3.2.1]octenes 1.32 can be
accessed through an intermolecular dipolar cycloaddition of kojic acid-derived salts 1.30 and
diversely-substituted alkynes 1.31 (Scheme 1.4).18

A key advantage of this approach is the introduction of functionality via readily available,
structurally diverse alkynes. Notably, salt 1.30 and related ylide sources have also found utility
in catalytic, asymmetric [5 + 2] dipolar cycloadditions,19 most recently with an array of
α,β-unsaturated aldehyde dipolarophiles,20 demonstrating the widespread utility of this starting
material. Moreover, 1.30a can be synthesized on a large scale from kojic acid, which is a very
inexpensive byproduct of sake production.21 Owing to the ease with which large quantities of
this salt can be synthesized, triflate salt 1.30a becomes a de facto starting material. Thus,
diversely substituted 8-oxabicyclo[3.2.1] octenes 1.32 are readily synthesized in one step.
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These bicyclic intermediates can undergo an acid-mediated ring-opening18,22 and
demethylation to generate multi-substituted αHTs in few steps from readily available 3-hydroxy4-pyrones (kojic acid). This route has proven to be useful in a broad range of optimization-driven
medicinal chemistry studies. Chiefly, it has been used to assess the antiviral properties of these
molecules.
Much of these medicinal chemistry efforts have been geared towards the development of
anti-HSV compounds. HSV-1 and -2 are highly related and destructive pathogens which
currently infect almost 4 billion people worldwide.23,24 They chronically infect superficially
damaged skin and mucosal surfaces, where they gain access to the nervous system and establish
lifelong latency. In addition to ulcerative diseases, they are also associated with a rare form of
encephalitis as well as corneal blindness.25 The current first line of treatment includes nucleoside
analog drugs such as acyclovir (ACV) and cidofovir (CDV).26-28 However, these clinical agents
are not completely effective, and the emergence of drug-resistant strains impedes efforts to
control HSV, particularly in immunocompromised adults29 and children.30 This drug resistance
therefore necessitates the development of new therapeutics.
Towards this end, Tavis, Morrison, and coworkers demonstrated that αHT natural
products manicol and β-thujaplicinol could inhibit wild-type and ACV-resistant HSV-1 and -2
replication in cellular assays.31 Our lab subsequently synthesized and tested a library of αHTs
against HSV to assess their viability as drug candidates.32 Among the top molecules to emerge
from this study was biphenyl 1.35, which exhibited nanomolar inhibition in HSV replication
assays that was improved over the natural product lead and first-line therapeutic ACV (Figure
1.3).
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Subsequent studies were conducted in an attempt to determine the binding target of
biphenyl αHT 1.35. Due to structural similarities with HIV RT RNase H,33 dinuclear
metalloenzyme terminase pUL15C emerged as a likely candidate, and thus an αHT-based SAR
study was conducted on this target in collaboration with Le Grice and coworkers.34 The best
molecule to emerge from the series was bromotropolone 1.36, which displayed improved binding
over the natural product lead in both inhibition and thermal stabilization experiments (Figure
1.4). However, antiviral lead 1.35 was found to bind weakly to pUL15C, suggesting that this
enzyme might not be the antiviral target. Studies are currently ongoing to identify the primary
target.35
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Nevertheless, the promising anti-HSV activity of αHTs has spurred SAR studies on other
members of the Herpesviridae family, most recently focused on Kaposi’s sarcoma herpesvirus
(KSHV).36 KSHV is the causative agent of Kaposi’s sarcoma,37 which remains one of the most
common cancers in people living with HIV.38 The virus is also responsible for certain types of
lymphomas and multicentric Castleman’s disease. These fatal diseases are currently largely
untreatable due to a lack of effective therapies.39 Therefore, new molecules are needed in order
to combat KSHV.
Fortunately, KSHV features a pUL15C-like terminase known as pORF29C, which we
considered a possible target for αHT inhibition. We thus examined inhibition of this enzyme by a
library of synthetic αHTs36 and discovered that dimethylester 1.37 demonstrated significant
thermal stabilization (Figure 1.5). As an extension of this finding, we sought to identify an
inhibitor of KSHV replication. Based on prior HSV studies,34 biphenyl 1.35 was analyzed. As
KSHV is primarily latent in the infected host, it must be reactivated in order to be susceptible to
an antiviral agent, and so these assays were run in a tetracycline repressed (TREx) latently
infected cell line in the presence of a known activator doxycycline. As expected, viral replication
was significantly reduced in the presence of DNA polymerase inhibitor phosphonoacetic acid
(PAA, 1.38). However, synthetic αHT 1.35 emerged as a more potent inhibitor, further reducing
viral growth at a significantly lower concentration than that of 1.38. At this same concentration
of 5 μM, 1.35 induced no cell death and so the antiviral effect is not due to cytotoxicity. These
results represent a promising lead for the development of anti-KSHV drugs.
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Synthetic αHTs have also demonstrated promising inhibitory activity towards dinuclear
metalloenzymes in other viral targets. Based on previous SAR studies focused on αHT inhibition
of HIV RT RNase H (vide supra),6e we tested our library of αHTs against this enzyme.40
Bromotropolone 1.36 was again identified as a potent substrate in both inhibition and thermal
stabilization assays. The molecules were additionally screened against HBV RT RNase H,41 and
while none of the synthetic constructs demonstrated improved enzymatic activity over the natural
product lead β-thujaplicinol, methyl ketone 1.39 was found to inhibit HBV viral replication with
an EC50 of 340 nM (Figure 1.6). This infers a therapeutic index of ~100 – a 4-fold increase over
the natural product lead. These studies all highlight the importance of synthesis in antiviral
development.

10

Although the majority of our ongoing research has been aimed at antiviral developments,
αHTs have demonstrated value towards other disease targets. The remainder of this chapter will
focus on αHT activity towards the aminoglycoside antibiotic resistance enzyme aminoglycoside2’’-O-nucleotidyltransferase [ANT(2’’)-Ia]. This enzyme is prevalent among Gram-negative
bacteria and is one of the most common determinants of enzyme-dependent aminoglycoside
resistance.42 Our oxidopyrylium cycloaddition/ring-opening strategy was used in the synthesis
and profiling of a library of synthetic αHTs against ANT(2’’)-Ia.43
1.5. Introduction to ANT(2’’)-Ia
Antibiotic resistance is a global health threat that jeopardizes not only our ability to treat
bacterial infections, but healthcare as we know it.44 Besides lifestyle changes,44f one strategy to
overcome resistance is to inhibit or disrupt resistance pathways in the form of antibiotic
adjuvants.45 For example, clavulanic acid is a β-lactamase inhibitor commonly used in tandem
with β-lactam antibiotics (such as amoxicillin, 1.40) to prolong their efficacy (Scheme 1.5).46
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Aminoglycoside antibiotics are also prone to this type of enzymatic deactivation.47 One
of these enzymes is ANT(2’’)-Ia, which catalyzes the adenylation of several clinically relevant
antibiotics including gentamicin and tobramycin, rendering them inactive (Scheme 1.6).48 This
target is prevalent among pathogenic Gram-negative bacteria, and has been ranked along with
N-acetyltransferase-6’ [AAC-(6’)] as the most common determinant of enzyme-dependent
aminoglycoside resistance in Pseudomonas aeruginosa.49 This is of particularly high clinical
relevance, as P. aeruginosa is the most common hospital-acquired Gram-negative infection.
Thus, inhibitors of ANT(2’’)-Ia could potentially find therapeutic utility when used in
combination with ANT(2’’)-Ia-susceptible aminoglycoside antibiotics.
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αHT, along with αHT natural product β-thujaplicinol, were identified as inhibitors of
ANT(2’’)-Ia in a 1982 study by researchers at Eli Lilly.50 Tropolone, meanwhile, showed no
activity against the enzyme, illustrating the importance of the 3 contiguous oxygens. While
several compounds have emerged for targeting aminoglycoside-modifying enzymes,51 in
particular aminoglycoside mimics,52 ANT(2’’)-Ia inhibitors have been elusive,53 and αHTs
remain one of the only leads.

1.6. Preliminary Substrate Scope and SAR
Our oxidopyrylium cycloaddition/ring-opening synthetic strategy was used in a
structure-function study of ANT(2’’)-Ia.43 The enzyme was overexpressed in Escherichia coli
BL21 (λDE3), and activity was monitored in 96 well format through the detection of
pyrophosphate (EnzCheck pyrophosphate assay), a by-product of the adenylation of gentamicin
(Scheme 1.6). All biological work was carried out by Prof. Gerard Wright and Dr. Georgina
Cox.

Previously

described

synthetic

α-hydroxytropolones18,22a

and

natural

product

β-thujaplicinol were tested for their inhibitory activity through an in vitro screen to obtain IC50
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values (Table 1.1). Ki experiments were obtained on active compounds (IC50 < 200 μM) through
dose curves with ATP and kanamycin B substrates.
Among the compounds tested, β-thujaplicinol was found to be capable of inhibiting the
enzyme with the greatest potency, with a Ki value of 6.4 μM. While the majority of the
synthesized molecules showed no inhibition of the enzyme, methyl ketone 1.39 and nitroaryl
1.54 demonstrated some inhibitory potency. Notably, these compounds were among the least
sterically demanding of the substrates tested and were approximately 5-10 fold less potent than
β-thujaplicinol, which is the least substituted. This trend suggests a sterically congested
enzymatic pocket.
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1.7. Speculation on Binding Mode
Previous studies suggest that the adenylation of ANT(2’’)-Ia may proceed via a
mechanism involving the two magnesium ions in the catalytic pocket of the enzyme. 54
Additionally, prior studies on αHT inhibition of ANT(2’’)-Ia demonstrated that activity is
influenced more substantially by ATP than by the aminoglycoside antibiotic.8 This trend was
also observed in our own studies. Furthermore, while direct binding of αHTs to ATP cannot be
entirely discounted, this mechanism of action appears unlikely due to the discrepancy between
the concentration of ATP (35 μM) and the observed IC50 values (as low as 6 μM) in the
inhibition assays.
More likely, the αHTs inhibit via competitive action with respect to ATP. In the instances
where Ki values were determined, all compounds demonstrated competitive inhibition with
respect to ATP and mixed inhibition with respect to the antibiotic. This suggests that αHTs bind
at or close to the ATP binding site, which is further supported by crystallographic data of
αHT-bound HIV RT RNase H (Figure 1.7A). These cocrystal structures exhibit a metal-metal
bond distance comparable to that found in an ATP-dinuclear enzyme complex (3.76 Å vs 3.91 Å,
respectively)55 (Figure 1.7B). Furthermore, recent crystallographic data54b,c of ANT(2’’)-Ia in
ternary complex with a nonhydrolyzable ATP analog (α,β-methyleneadenosine 5’-triphosphate
lithium salt, AMPCPP) and gentamicin shows coordination of both divalent metal ions by
AMPCPP phosphate groups as well as several Asp residues (Figure 1.7C).54c This suggests that
the magnesium ions function as mediators of ATP transfer to the aminoglycoside substrate. αHT
inhibition therefore likely occurs via inhibition of this mechanism.

15

Furthermore, tropolone is generally inactive against ANT(2’’)-Ia, and additional
methylated congeners of active compounds 1.39 and 1.54 (1.39a and 1.54a respectively, Table
1.1) accessible through our synthetic method were also found to be inactive. While this could be
due to other effects such as steric impacts of the added methyl group, this data is consistent with
a dimetallic chelation binding mode.

1.8. Follow-Up Substrate Scope and SAR
We subsequently began to synthesize derivatives of the two lead synthetic αHTs, 1.39
and 1.54. Using the same oxidopyrylium cycloaddition/ring-opening route, a series of analogs
was generated and assayed (Table 1.2). Among the ketones tested, only isopropyl ketone 1.62
showed any significant activity, which was comparable to 1.39. Cyclohexyl derivatives 1.63 and
1.64 were inactive, potentially due to the aforementioned steric demands of the binding pocket.
Additional support for the hypothesis of a sterically demanding enzymatic pocket can be
found among the aryl series. Phenyl derivative 1.56 demonstrated comparable activity to parent
molecule 1.54, while naphthyl derivatives 1.57 and 1.58 showed no activity. Comparisons
among electron-withdrawing-substituted aryls further support this hypothesis. Halogenated
analogs 1.59 and 1.60 both showed an almost 4-fold increase in activity over the other synthetic
16

constructs; meanwhile, trifluoromethyl aryl 1.61 demonstrated no inhibition of the enzyme,
presumably due to the steric effects of the CF3 group even while electronic considerations
remained consistent.

1.9. Assessment of Synergistic Activity
With a series of ANT(2’’)-Ia-inhibiting troponoids in hand, we subsequently sought to
assess whether these molecules could rescue the activity of aminoglycoside antibiotics against
ANT(2’’)-Ia-expressing bacteria. Occasionally, molecules that demonstrate potent enzymatic
activity will show a lack of antibacterial activity in cells.56 This is typically attributed to issues
with cell permeability and/or the molecule being removed from the cell via efflux pumps.
Therefore, a hyper-permeable, ANT(2’’)-Ia-expressing strain of E. coli BW25113 was
constructed,57 leading to gentamicin resistance (MIC of 64 μg/mL vs. 0.25 μg/mL for wild type).
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These bacteria were treated with gentamicin and the αHTs in a checkerboard fashion in order to
assess their ability to potentiate the activity of the antibiotic (Figure 1.8).
Quantitatively, synergy can be determined by calculating each molecule’s FIC index
(FICI)58 according to CLSI guidelines (Eq. 1.1).59

Eq. 1.1

FICI values of less than 0.5 are considered indicative of synergistic activity, while values of 0.5
– 4 are classified as indicative of no interaction, and FICI values > 4 demonstrate antagonistic
activity.45 Qualitatively, the shaded portions of the 2D graphs of synergistic molecules (FICI <
0.5) are triangular in shape as a result of the concerted effects of the αHT and gentamicin.

18

Consistent with the previous reports from Eli Lilly,8 β-thujaplicinol demonstrated
synergy with gentamicin in our experiments (FICI = 0.375). As a negative control, an alternative
enzyme conferring resistance to gentamicin (aminoglycoside phosphotransferase [APH(2’’)-Id])
that is uninhibited by αHTs was expressed by E. coli. β-thujaplicinol showed no synergy with
this enzyme, which indicates that this activity is likely due to inhibition specifically of
ANT(2’’)-Ia and not simply of ATP-binding proteins.
Synergistic activity was also observed with ketones 1.39 and 1.62. ANT(2’’)-Iainhibiting biaryls 1.54, 1.55, 1.59 and 1.60 were all synergistically inactive. While the reason for
this activity is currently unclear, a few possibilities exist such as low cell permeability, active
efflux from the cell, and off-target interactions of the αHTs.
Interestingly, the checkerboard analysis revealed a difference in relative activity between
β-thujaplicinol and synthetic construct 1.39. At 12 μM of β-thujaplicinol and 1.39, gentamicin
had an MIC of 8 μg/mL and 32 μg/mL, respectively (see Figure 1.8). This trend reflects the
difference in activity determined in the ANT(2’’)-Ia inhibition assay. However, at a 50 μM
concentration of β-thujaplicinol all bacterial cells had died, while a considerable amount of cells
(~80%) remained at the same concentration of 1.39. At these higher concentrations of 1.39, no
growth was seen at the lowest concentration of gentamicin tested (2 μg/mL). Thus, the highest
non-toxic concentrations of 1.39 were more effective at restoring antibiotic activity than the
highest non-toxic concentrations of β-thujaplicinol. Though not directly therapeutically useful, it
does imply that 1.39 could have advantages over β-thujaplicinol in studying ANT(2’’)-Ia
inhibition in cell-based assays where background antibacterial activity is a hindrance.
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1.10. Conclusions
A library of αHTs were synthesized and tested for their inhibition of ANT(2’’)-Ia.
Several were identified as potent inhibitors, and two were found to have additional specific
synergistic activity with gentamicin against gentamicin-resistant, ANT(2’’)-Ia-expressing E. coli.
One of these compounds has significantly less background antibacterial activity with respect to
E. coli than the natural product lead, β-thujaplicinol, and could have advantages in the study of
the

enzyme

in

cell-based

assays.

These

results

validate

the

oxidopyrylium

cycloaddition/ring-opening method as a viable approach to generating new ANT(2’’)-Ia
inhibitors, and provide some preliminary insight into the structural changes required for
inhibitory activity and cellular efficacy.
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1.12. Supplementary Experimental Details
Drs. Michael P. D’Erasmo and Christine Meck performed some of the synthetic work and
Dr. Georgina Cox performed the biological assays for this study. All of the experimental details
can be found in the Supporting Information for the publications on which this chapter is based.S1,S2
This material is available free of charge at the ACS (http://pubs.acs.org) and at ScienceDirect
(https://www.sciencedirect.com).

1.12.1. General Information
All starting materials and reagents were purchased from commercially available sources
and used without further purification, with exception of CH2Cl2, which was purified on a solvent
purification system prior to the reaction. 1H NMR shifts are measured using the solvent residual
peak as the internal standard (CHCl3 δ 7.26), and reported as follows: chemical shift, multiplicity
(s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, q = quartet, m =
multiplet), coupling constant (Hz), and integration. 13C NMR shifts are measured using the solvent
residual peak as the internal standard (CDCl3 δ 77.20), and reported as chemical shifts. Infrared
(IR) spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w).
Microwave reactions were performed via the Biotage Initiator 2.5. Purification via column
chromatography was performed on the Biotage Isolera Prime, with Biotage SNAP 10g or 25g
cartridges, in a solvent system of ethyl acetate and hexanes.
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1.12.2. Synthesis and Characterization of 8-oxabicyclo[3.2.1]octenes (S1.1a-d)

General Procedure. To a solution of salt 1.30aS2 and alkyne (5-10 equiv) in CHCl3 (0.5 M) was
added N,N-diisopropylaniline (1.2 equiv). The reaction mixture was subjected to microwave
irradiation at 100 °C for one hour. Reaction mixture was then loaded directly onto column for
chromatography and purified.

3-methoxy-5-methyl-6-(naphthalen-1-yl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (S1.1a). To
a solution of salt 1.30a (108.2 mg, 0.373 mmol) and 1-ethynylnapthalene (527 μL,
3.73 mmol) in CDCl3 (746 μL) was added N,N-diisopropylaniline (87 μL, 0.447
mmol). After microwave irradiation at 100 °C for 60 min, the reaction mixture was
purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 5%
EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% EtOAc in hexanes (10 CV);
10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 CV)). Product fractions were
concentrated to yield S1.1a as an orange oil (85.7 mg, 79% yield). Rf= 0.30 in 25% EtOAc in
hexanes. IR (thin film, KBr) 3057 (w), 2978 (w), 2930 (w), 2836 (w), 1710 (s), 1605 (m) 1345
(w), 1268 (w), 1132 (m), 1117 (w), 989 (w), 778 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 8.05 –
7.94 (m, 1H), 7.91 – 7.67 (m, 2H), 7.58 – 7.35 (m, 3H), 7.22 (d, J = 1.2 Hz, 1H), 6.39 (d, J = 2.2
Hz, 1H), 6.16 (s, 1H), 5.18 (d, J = 2.5 Hz, 1H), 3.67 (s, 3H), 1.51 (s, 3H). 13C NMR (100 MHz,
CDCl3) δ 190.2 (s), 156.5 (s), 145.9 (s), 134.0 (s), 131.6 (s), 131.6 (s), 128.8 (s), 128.7 (s), 126.8
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(s), 126.7 (s), 126.5 (s), 125.7 (s), 125.1 (s), 123.7 (s), 120.2 (s), 88.2 (s), 86.8 (s), 55.0 (s), 21.6
(s).

3-methoxy-5-methyl-6-(naphthalen-2-yl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (S1.1b). To
a solution of salt 1.30a (17.0 mg, 0.058 mmol) and 2-ethynylnapthalene (88.9 mg,
0.584 mmol) in CDCl3 (117 μL) was added N,N-diisopropylaniline (13.7 μL, 0.070
mmol). After microwave irradiation at 100 °C for 60 min, the reaction mixture was
purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 5%
EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% EtOAc in hexanes (10 CV);
10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 CV)). Product fractions were
concentrated to yield S1.1b as a yellow oil (14.4 mg, 84% yield). Rf= 0.28 in 25% EtOAc in
hexanes. IR (thin film, KBr) 3056 (w), 2963 (w), 2933 (w), 2837 (w), 1708 (m), 1605 (w), 1174
(w), 1344 (w), 1131 (m), 1101 (w), 867 (w), 694 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 7.89 –
7.80 (m, 3H), 7.71 (d, J = 1.5 Hz, 1H), 7.55 – 7.48 (s, 1H), 7.44 (d, J = 1.7 Hz, 1H), 7.40 (d, J =
1.8 Hz, 1H), 6.41 (d, J = 2.5 Hz, 1H), 6.30 (s, 1H), 5.05 (d, J = 2.5 Hz, 1H), 3.64 (s, 3H), 1.76 (s,
3H). 13C NMR (50 MHz, CDCl3) δ 190.2 (s), 159.0 (s), 146.4 (s), 133.5 (s), 133.4 (s), 130.7 (s),
128.9 (s), 128.5 (s), 128.1 (s), 127.1 (s), 127.0 (s), 125.0 (s), 124.4 (s), 123.7 (s), 119.5 (s), 86.8
(s), 86.2 (s), 55.1 (s), 22.7 (s).

6-(4-chlorophenyl)-3-methoxy-5-methyl-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one (S1.1c). To a
solution of salt 1.30a (100.0 mg, 0.344 mmol) and 1-chloro-4-ethynylbenzene (469.83
mg, 3.44 mmol) in CHCl3 (689 μL) was added N,N-diisopropylaniline (80 μL, 0.413
mmol). After microwave irradiation at 100 °C for 60 min, the reaction mixture was
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purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient: 5%
EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10% EtOAc in hexanes (10 CV);
10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8 CV)). Product fractions were
concentrated to yield S1.1c as a yellow solid (37.8 mg, 40% yield). Melting Point (MP) = 138-141
°C. Rf= 0.27 in 25% EtOAc in hexanes. IR (thin film, KBr) 3066 (w), 2974 (w), 2935 (w), 2839
(w), 1711 (s), 1604 (m), 1490 (w), 1174 (w), 1131 (w), 1092 (w), 864 (w), 827 (w) cm-1. 1H NMR
(200 MHz, CDCl3) δ 7.36 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 6.29 (d, J = 2.3 Hz, 1H),
6.16 (s, 1H), 4.98 (d, J = 2.5 Hz, 1H), 3.60 (s, 3H), 1.66 (s, 3H). 13C NMR (100 MHz, CDCl3) δ
189.9 (s), 157.9 (s), 146.2 (s), 134.8 (s), 131.7 (s), 129.2 (s), 127.5 (s), 123.9 (s), 119.2 (s), 86.5
(s), 85.9 (s), 55.0 (s), 22.3 (s).

3-methoxy-5-methyl-6-(4-(trifluoromethyl)phenyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(S1.1d). To a solution of salt 1.30a (100.2 mg, 0.345 mmol) and 1-ethynyl-4(trifluoromethyl)benzene (563 μL, 3.45 mmol) in CDCl3 (690 μL) was added N,Ndiisopropylaniline (80 μL, 0.414 mmol). After microwave irradiation at 100 °C for 60
min, the reaction mixture was purified by chromatography (Biotage Isolera Prime, 25 g silica gel
column, solvent gradient: 5% EtOAc in hexanes (3 CV); 2-5% EtOAc in hexanes (8 CV); 5-10%
EtOAc in hexanes (10 CV); 10-20% EtOAc in hexanes (10 CV); 20-35% EtOAc in hexanes (8
CV)). Product fractions were concentrated to yield S1.1d as a yellow oil (77.6 mg, 72% yield).
Rf= 0.30 in 25% EtOAc in hexanes. IR (thin film, KBr) 3063 (w), 2981 (w), 2938 (w), 2840 (w),
1713 (s), 1606 (m), 1410 (w), 1327 (s), 1129 (s), 1016 (m), 865 (w), 832 (w) cm-1. 1H NMR (200
MHz, CDCl3) δ 7.63 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.1 Hz, 2H), 6.40 (d, J = 2.5 Hz, 1H), 6.16
(s, 1H), 5.01 (d, J = 2.5 Hz, 1H), 3.60 (s, 1H), 1.66 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 189.7
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(s), 157.8 (s), 146.3 (s), 136.9 (s), 130.9 (q, J = 32.8 Hz), 126.6 (s), 126.0 (q, J = 3.8 Hz), 125.9
(s), 124.2 (q, J = 272.1 Hz), 118.9 (s), 86.6 (s), 86.2 (s), 55.1 (s), 22.3 (s).

1.12.3. Synthesis and Characterization of αHTs via One-Pot TfOH/HBr/AcOH

General Procedure. In a 15 mL round-bottom flask was placed a solution of 8oxabicyclo[3.2.1]octene S1.1 in CHCl3 (0.1 M). To the solution at rt was added 4 equivalents of
triflic acid. The mixture was stirred for 30 minutes before quenching with an equivalent volume
of pH 7 phosphate buffer and extracting with CH2Cl2 to isolate the methoxytropolone. To this
compound was added HBr in AcOH (33%) at reflux for 4 hours. Reaction mixture was then
quenched to pH 5 using a pH 7 phosphate buffer and extracted with CH2Cl2.

2,7-dihydroxy-4-methyl-5-(naphthalen-1-yl)cyclohepta-2,4,6-trienone (1.57). To a solution of
bicycle S1.1a (35.6 mg, 0.1218 mmol) in CDCl3 (1.22 mL) was added triflic
acid (43.1 μL, 0.487 mmol). The reaction was allowed to stir for 30 minutes at
rt before quenching to pH 7 with pH 7 phosphate buffer and extracting with CH2Cl2 (5 x 10 mL).
Combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure.
To the isolated methoxytropolone (18.2 mg) was added 800 μL 33% HBr/AcOH solution. The
reaction was heated to reflux (120 °C) for 7 hours before being quenched to pH 6 with 10 mL of
pH 7 phosphate buffer. The organic layer was isolated and the aqueous layer was extracted with
CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated under
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reduced pressure to yield 1.57 as a brown oil (13.4 mg, 77% yield). IR (thin film, KBr) 3248 (br),
1526 (m), 1447 (w), 1383 (m), 1278 (w), 1239 (w), 1220 (w), 1086 (w), 783 (w), 730 (w) cm-1.
1H

NMR (200 MHz, CDCl3) δ 7.92 (dd, J = 7.8, 4.3 Hz, 2H), 7.63 (s, 1H), 7.52 (s, 1H), 7.61 –

7.27 (m, 5H), 2.08 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.9 (s), 158.3 (s), 156.8 (s), 147.4
(s), 142.1 (s), 138.9 (s), 130.9 (s), 130.6 (s), 130.3 (s), 129.2 (s), 129.1 (s), 126.0 (s), 125.7 (s),
124.5 (s), 123.7 (s), 123.0 (s), 30.0 (s), 26.5 (s).

2,7-dihydroxy-4-methyl-5-(naphthalen-2-yl)cyclohepta-2,4,6-trienone (1.58). To a solution of
bicycle S1.1b (42.4 mg, 0.145 mmol) in CDCl3 (1.45 mL) was added triflic
acid (51.3 μL, 0.580 mmol). The reaction was allowed to stir for 30 minutes at
rt before quenching to pH 6 with pH 7 phosphate buffer and extracting with
CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated under
reduced pressure. To the isolated methoxytropolone (15.6 mg) was added 686 μL 33% HBr/AcOH
solution. The reaction was heated to reflux (120 °C) for 8 hours before being quenched to pH 6
with 10 mL of pH 7 phosphate buffer. The organic layer was isolated and the aqueous layer was
extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and
concentrated under reduced pressure to yield 1.58 as a brown oil (12.5 mg, 85% yield). IR (thin
film, KBr) 3248 (br), 1526 (w), 1446 (w), 1392 (w), 1284 (w), 1231 (w), 1205 (w), 1122 (w),
1092 (w), 907 (w), 858 (w) 795 (w), 730 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 7.89 (m, 3H),
7.71 (s, 1H), 7.61 (s, 1H), 7.59 (s, 1H), 7.55 (dd, J = 2.9 Hz, 1H), 7.55 (d, J = 9.5 Hz, 1H), 7.36
(dd, J = 8.4, 1.6 Hz, 1H), 2.29 (s, 3H).

13C

NMR (100 MHz, CDCl3) δ 167.62 (s), 158.13 (s),

156.79 (s), 143.95 (s), 141.39 (s), 139.43 (s), 133.58 (s), 132.87 (s), 128.64 (s), 128.40 (s), 128.14
(s), 127.52 (s), 127.06 (s), 126.87 (s), 126.76 (s), 124.59 (s), 53.75 (s), 26.82 (s).
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4-(4-bromophenyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.59). To a solution of
previously-made 8-oxabicyclo[3.2.1]octene intermediateS3 (17.6 mg, 0.0548
mmol) in CDCl3 (548 μL) was added triflic acid (19.4 μL, 0.219 mmol). The
reaction was allowed to stir for 30 minutes at rt before quenching to pH 6 with
pH 7 phosphate buffer and extracting with CH2Cl2 (5 x 10 mL). Combined organics were dried
over Na2SO4, filtered, and concentrated under reduced pressure. To the isolated methoxytropolone
(12.5 mg) was added 550 μL 33% HBr/AcOH solution. The reaction was heated to reflux (120 °C)
for 4 hours before being quenched to pH 5 with 10 mL of pH 7 phosphate buffer. The organic layer
was isolated and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics
were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 1.59 as an
orange/brown oil (10.3 mg, 86% yield). IR (thin film, KBr) 3248 (br), 1528 (m), 1487 (w), 1447
(w), 1388 (w), 1279 (w), 1208 (w), 1128 (w), 1092 (w), 1072 (w), 1012 (w), 814 (w), 669 (w) cm1 1
. H

NMR (200 MHz, CDCl3) δ 7.58 (d, J = 6.8 Hz, 2H), 7.43 (s, 1H), 7.26 (s, 1H), 7.12 (d, J =

8.4 Hz, 2H), 2.23 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.61 (s), 158.35 (s), 156.55 (s), 142.76
(s), 142.52 (s), 139.09 (s), 132.21 (s), 130.36 (s), 124.54 (s), 124.00 (s), 122.43 (s), 26.79 (s).

4-(4-chlorophenyl)-2,7-dihydroxy-5-methylcyclohepta-2,4,6-trienone (1.60). To a solution of
bicycle S1.1c (19.2 mg, 0.0694 mmol) in CHCl3 (694 μL) was added triflic acid
(24.5 μL, 0.278 mmol). The reaction was allowed to stir for 30 minutes at rt
before quenching with sodium acetate (56.9 mg, 0.693 mmol). After stirring for
an additional 15 minutes, the solution was concentrated under reduced pressure. To the mixture
was added 696 μL AcOH and 151 μL 33% HBr/AcOH solution. The reaction was heated to 90 °C
for 4 hours before being quenched to pH 5 with 10 mL of pH 7 phosphate buffer. The organic layer
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was isolated and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Upon finding clean
conversion to the methoxytropolone, the product was resubjected to the HBr/AcOH reflux
conditions (847 μL 33% HBr/AcOH solution, 120 °C) for two hours to yield 1.60 as a black oil
(16.5 mg, 90% yield). IR (thin film, KBr) 3066 (w), 2974 (w), 2935 (w), 2839 (w), 1711 (s), 1604
(m), 1490 (w), 1174 (w), 1131 (w), 1092 (w), 864 (w), 827 (w) cm-1. 1H NMR (200 MHz, CDCl3)
δ 7.56 (s, 1H), 7.43 (s, 1H), 7.42 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 2.24 (s, 3H). 13C
NMR (100 MHz, CDCl3) δ 167.62 (s), 158.11 (s), 156.78 (s), 142.55 (s), 139.09 (s), 134.04 (s),
130.14 (s), 129.31 (s), 124.55 (s), 124.04 (s), 29.99 (s), 26.83 (s).

2,7-dihydroxy-4-methyl-5-(4-(trifluoromethyl)phenyl)cyclohepta-2,4,6-trienone (1.61). To a
solution of bicycle S1.1d (27.3 mg, 0.0880 mmol) in CDCl3 (880 μL) was
added triflic acid (31.1 μL, 0.352 mmol). The reaction was allowed to stir for
30 minutes at rt before quenching to pH 7 with pH 7 phosphate buffer and
extracting with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and
concentrated under reduced pressure. To the isolated methoxytropolone (10.5 mg) was added 461
μL 33% HBr/AcOH solution. The reaction was heated to reflux (120 °C) for 7 hours before being
quenched to pH 5 with 10 mL of pH 7 phosphate buffer. The organic layer was isolated and the
aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 1.61 as a brown oil (6.3 mg,
63% yield). IR (thin film, KBr) 3247 (br), 1617 (w), 1530 (m), 1392 (w), 1324 (s), 1281 (w),
1166 (w), 1126 (m), 1068 (m), 1017 (w), 822 (w) cm-1. 1H NMR (200 MHz, CDCl3) δ 7.72 (d, J
= 8.5 Hz, 2H), 7.58 (s, 1H), 7.41 (s, 1H), 7.38 (d, J = 8.5 Hz, 2H), 2.24 (s, 3H). 13C NMR (100
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MHz, CDCl3) δ 167.8 (s), 158.3 (s), 156.8 (s), 147.4 (s), 142.1 (s), 138.9 (s), 130.4 (q, J = 32.7
Hz), 129.1 (s), 126.0 (q, J = 3.7 Hz), 124.5 (s), 124.3 (q, J = 270.0 Hz) 123.7 (s), 26.7 (s).

1.12.4. NMR Spectra of Synthesized Compounds
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Chapter II
Synthesis and Biological Assessment of 3,7-Dihydroxytropolones
2.1. Introduction
7-Hydroxytropolones (α-hydroxytropolones, or αHTs; 2.1a) and 3,7-dihydroxytropolones
(3,7-dHTs, 2.1b) (Scheme 2.1A) are troponoids with three and four contiguous oxygen atoms,
respectively, and display an extraordinarily broad range of biological activity.1 While this activity
is most often attributed in both cases to their ability to serve as metal binding fragments for many
physiologically relevant dinuclear metalloenzymes (2.2, Scheme 2.1A), stark differences in
bioactivity have been observed
between them. For example, αHTs
appear to be substantially more
potent than 3,7-dHTs as inhibitors of
HIV ribonuclease H,2,3 a promising
target

for

HIV

antivirals

that

remains untargeted clinically, as
well

as

aminoglycoside-2″-O-

nucleotidyltransferase, one of the
most

common

determinants

of

enzyme-dependent aminoglycoside
resistance

in

Pseudomonas

aeruginosa.4 On the other hand, the
3,7-dHT natural product puberulic
acid

has

demonstrated

potent
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antimalarial activity, with selectivity on par with clinical agent artesunate, whereas in similar
assays αHTs have substantially lower potency and selectivity.5 3,7-dHT also possesses activity
against B16 melanoma cells an order of magnitude greater than αHTs, and increases the lifespan
of mice bearing B16 melanoma comparably to mice administered the chemotherapeutic agent
mitomycin C.6
In order to better understand the nuances of structure-bioactivity differences between αHTs
and 3,7-dHTs, efficient synthetic methods are needed to access both classes, and of particular value
would be those that also allow comparable substitution.7 Recently, a galactose-based method
previously used by Sunazuka and Omura to synthesize puberulic acid8 was further adapted to
develop a small library of both 3,7-dHTs and αHTs (Scheme 2.1B), as well as other related
troponoids.9 Testing of these molecules for their antimalarial activity revealed that a carboxylic
acid was key to providing selectivity against Plasmodium falciparum K1 versus MRC-5 cells, and
it did so whether on an αHT or a 3,7-dHT, but provided more selectivity with 3,7-dHT. These
studies highlight the value of a divergent, unifying strategy in SAR determination of oxygenated
troponoids, and their importance in assessing the inhibitory potential of these oxygenated
troponoids.
Our lab has previously reported an extremely efficient oxidopyrylium cycloaddition/ring
opening strategy for αHT synthesis that has to date generated over 50 published αHTs with varying
substitution patterns,10,11 and has been used to provide SAR and pursue synthetic chemistry-based
optimization studies related to various human diseases.12-18 We herein report the adaptation of this
route to access a series of 3,7-dHTs. We highlight this strategy through the synthesis of a potential
biosynthetic precursor to the 3,7-dHT natural products puberulonic and puberulic acid. The
molecules were assessed as part of biochemical and biological studies related to HIV, hepatitis B
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virus (HBV), and herpes simplex virus (HSV)-1 and -2. These studies help provide an
understanding of the advantages and disadvantages of 3,7-dHTs and αHTs as chemotypes for drug
discovery and development.

2.2. Synthesis of 3,7-Dihydroxytropolones
2.2.1. Preliminary Library of 3,7-dHTs
Our synthesis started with a cycloaddition between oxidopyrylium triflate salt 2.8a, which
can be made on gram scale in 3 steps from commercially-available kojic acid,19 and
iodopropiolates (Scheme 2.2A, 2.12a/b), which are prepared from the corresponding propiolates
using silver nitrate and N-iodosuccinimide.20,21 Bromopropiolates are also capable of efficient
oxidopyrylium cycloaddition and have been used in the synthesis of bromohydroxytropolones,14
but their volatility and strong lachrymator properties pose technical challenges.
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The iodobicycles can then be converted into methoxybicycles through a DMAP-catalyzed
methanolysis (2.13a/b → 2.14a/b). These conditions were deemed necessary when we found that
Brønsted base-mediated methanolysis led to dimethyl acetals (e.g. 2.13d), while DMAP
incorporation was observed as the major product when chloroform was employed as the solvent
in an attempt at hydrolysis (2.13c, Scheme 2B). Interestingly, subsequent ring-opening attempts
on these bicycles (2.14a/b → 2.15a/b) using sulfonic acids led to formation of oxidopyrylium
dimers as the major product, as observed by crude 1H-NMR (e.g. 2.17a, Scheme 2.2C). We
hypothesize that this may proceed via protonation and elimination of the β-methoxyenoate 2.20,
which would lead to a rapidly dimerizing oxidopyrylium ylide (2.8* → 2.17a).22 Fortunately, an
alternative procedure using the Lewis acid boron trichloride promoted clean conversion to
3,7-dimethoxytropolones 2.15a and 2.15b, which were subsequently converted to the 3,7-dHTs
2.16a and 2.16b using hydrobromic acid in acetic acid at elevated temperatures.
Additionally, in the presence of excess water along with extended reaction times, methyl
ester 2.15a was readily decarboxylated (2.16c, Scheme 2.2D), which can be attributed to the
participation of a β-keto acid tautomer. Thus, while the ester provides a convenient synthetic
handle for efficient oxidopyrylium cycloaddition and subsequent iodide for methoxide exchange,
it can be readily removed if desired.

2.2.2. Synthetic Efforts Towards Total Synthesis of a Potential Biosynthetic Intermediate
With an efficient method for 3,7-dHT synthesis in hand, we sought to test the new strategy
in total synthesis. The two most widely studied 3,7-dHTs are puberulonic and puberulic acid,
which have been isolated from the fungus Penicillum puberulum.23 These natural products are also
close structural homologs of the 6-hydroxytropolones stipitatonic and stipitatic acid,24 the focus of
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recent biosynthetic studies by Cox and coworkers.25 These studies demonstrated that stipitatic acid
is formed from stipitatonic acid, which is, in turn, formed from the lactone stipitalide (2.21,
Scheme 2.3). While a similar biosynthetic pathway seems plausible for puberulonic and puberulic
acid, the 3,7-dHT stipitalide homolog 2.16d is unknown. Access to this molecule could be useful
in elucidating the biosynthesis of puberulic and puberulonic acid, and our synthetic strategy
appeared uniquely well suited for this task. Thus, we set out to conduct a total synthesis of 2.16d.

We began our synthesis with the chloromethylene-containing oxidopyrylium salt 2.8b
(Scheme 2.4). Initial attempts towards bicycle 2.13e using our prior conditions (‘a’, Scheme 2.4)
lead to a significant amount of compound 2.13b, which created purification challenges given the
similar polarities of 2.13b and 2.13e. We hypothesized that this product was formed through a
hydride transfer from the N,N-diisopropylaniline,26 and thus, leveraging the readily reversible
nature of this class of oxidopyrylium ylides (formed following deprotonation of 2.8b),10 we
synthesized and isolated dimer 2.17b as the source of the ylide.27 Indeed, this alternative procedure
led to the dihalogen 2.13e without any noticeable 2.13b. While this intermediate offered two
electrophilic handles, namely a β-iodoacrylate for methanolysis and a primary alkyl chloride for
eventual lactonization, we reasoned that the alkyl chloride would be stable to the methanolysis
conditions because of the adjacent tertiary center. Indeed, methanolysis of 2.13e proceeded
efficiently while maintaining the chloride’s integrity, even though higher temperatures were
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needed for this transformation than for 2.13a/b. Subsequent ring-opening afforded
methoxytropolone 2.15c, which was then advanced to 2.16d through a three-step acetolysis/
lactonization/demethylation sequence. During the course of these studies, we also discovered that
reverse-phase chromatography of 2.15c facilitated on-column lactonization to afford 2.15e,
providing a more direct synthetic method.

2.3. Biological Studies of αHTs versus 3,7-dHTs
2.3.1. HIV-Associated Activity
One of the more active areas of research in our group has been αHT antiviral development,
as several viral nucleases have been identified as targets for these molecules.2,3,13-18 The most
widely studied in these contexts is the ribonuclease H function of HIV reverse transcriptase (HIV
RT RNaseH),2,3,13,28-30 a promising candidate for therapeutic development that remains untargeted
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clinically. αHTs are potent inhibitors of the enzyme with 50% inhibition concentrations (IC50) less
than 200 nM, and several synthetic αHTs have been developed with modest antiviral activity in
cell-based assays.2,13,29 While both 3,7-dHTs and αHTs are known inhibitors of the enzyme, and
the collection of literature sources indicate that αHTs are superior inhibitors, head-to-head
comparisons of both classes of molecules have not to the best of our knowledge been conducted.
We thus tested 3,7-dHTs 2.16a–2.16d, αHT congener 2.26, and methoxytropolone congeners
2.15a and 2.27 for their ability to inhibit HIV-1 RT RNaseH.
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Consistent with literature trends, αHT 2.26 was the most potent of the compounds tested, with a
4–5 fold increase over the 3,7-dHTs (Figure 2.1). Methoxytropolones were even less potent,
consistent with tropolone activity. Furthermore, while promising cell-based HIV antiviral activity
of 3,7-dHT has been described in the literature,3 our synthetic 3,7-dHTs showed no protective
effects, possibly due to a combination of weaker anti-RNaseH activity and higher cytotoxicity.
Compound 2.26, which is known to have modest HIV protective effects,13 was tested
simultaneously as a positive control. Thus, early indications suggest that the extra hydroxyl in
3,7-dHTs is unfavorable for HIV therapeutic development targeting RNaseH.

2.3.2. HBV-Associated Activity
Hepatitis B also has an RNase H function that has become a target for antiviral drug
development, and αHTs have emerged as one of the most promising scaffolds.31 A 3,7-dHT has
never been tested for this activity, and thus we assessed our new compounds’ HBV RNase
H-specific antiviral activity by monitoring the amount of viral (+)-DNA strand versus (−)-DNA,
since inhibiting RNase H activity suppresses production of the former. As expected, αHT 2.26
showed only minor cytotoxicity against the host cell line, HepDES19, while selectively inhibiting
synthesis of the viral (+)-DNA. Selective inhibition of viral (+)-DNA was also observed with
3,7-dHTs 2.16a and 2.16b, although they were significantly more cytotoxic. It is worth noting the
structural similarities of the two selective inhibitors, 2.16a and 2.16b, to compound 2.26 and the
lack of activity of compound 2.16c, which could indicate an important role of the carbonyl
appendage. Unfortunately, the EC50 values of the viral suppression of 2.16a/b coupled with their
CC50 values revealed virtually no therapeutic window, as compared to the 60-fold window of αHT
2.26. Thus, while these experiments demonstrate antiviral potential for 3,7-dHTs that may warrant
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further studies, early indications suggest they are not advantageous over αHTs. On the other hand,
the 3,7-dimethoxytropolone 2.15a displayed moderate inhibition selectivity for (+)-DNA, had an
antiviral EC50 value of 5.5 μM, and was nontoxic at concentrations of up to 100 μM. Thus,
3,7-dimethoxytropolone appears to be a viable chemotype for further anti-HBV development.

2.3.3. HSV-associated activity
While 3,7-dHTs had never been tested for anti-HSV activity prior to our studies, αHTs
were identified as anti-HSV agents, with the natural product manicol displaying antiviral EC50
values against HSV-1 and -2 of 350 nM and 580 nM, respectively.32 Furthermore, tests against 20
synthetic αHTs synthesized through our oxidopyrylium cycloaddition/ring opening procedure
identified a synthetic αHT with antiviral EC50 values against HSV-1 and -2 of 120 nM and 80 nM,
respectively (see 2.28, Figure 2.3).15 In all cases, cytotoxicity was not observed against Vero cells
within the 24 hours experiment. We thus tested our library of tropolones and found that 3,7-dHTs
2.16a, 2.16b, and 2.16c all strongly inhibited replication of HSV-1 at a concentration of 5 μM,
with suppression levels comparable to the therapeutic anti-HSV agent acyclovir (ACV) and
exceeding that of cidofovir (CDV) (Figure 2.2A). αHT 2.26 only showed moderate replication
inhibition at 5 μM, and no activity at 1 μM, whereas the activity for 2.16a–2.16c was maintained.
Methoxytropolones 2.15a and 2.27 were the least active compounds among the series tested.
3,7-dHT 2.16d was inactive, illustrating how changes in the side-chains can impact activity.
3,7-dHTs 2.16a–c inhibited HSV-2 replication with comparable suppression levels and potencies,
and this activity was maintained against three other HSV-2 clinical isolates at 5 μM (Figure 2.2B).
The EC50 values of compounds 2.16a and 2.16c were comparable to ACV for HSV-1, and showed
no cytotoxicity versus the Vero cell line at up to 100 μM for 24 hours (Figure 2.2C). Furthermore,
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while ACV was nearly an order of magnitude less potent against HSV-2 than HSV-1, 2.16a and
2.16c maintained significant potency.
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2.3.4. Mechanistic Insights on Mode of Action
Although the mechanism of action is currently under investigation, experiments with 2.16a
against the ACV-resistant TK-HSV-1 and HSV-2 strains confirmed a different mechanism of
action than ACV (Figure 2.2B). One hypothesis is that the molecules could engage one or more
viral nucleotidyltransferases.33 For example, the HSV-1 DNA packing terminase pUL15 encodes
a C-terminal nuclease activity that can be inhibited by αHTs.14,34 Thus, we tested 3,7-dHTs against
recombinant pUL15C and found them to be inhibitors of the enzyme, but with less potency than
αHT 2.26 (Figure 2.2C).
Given the SAR suggesting benefits of the additional oxygen for HSV inhibition potency, a
3,7-dHT analog of the most potent anti-HSV αHT described to date, compound 2.28, was
synthesized (2.16e, Scheme 2.5).

Anti-HSV-1 activity was assessed in parallel with 3,7-dHT 2.16a and αHTs 2.28 and 2.26 (Figure
2.3B). As expected, compound 2.26 showed no antiviral activity, even at 5 μM, whereas some
viral suppression was observed for 2.28, 2.16a and 2.16e. At 1 μM, 2.16e and 2.28 antiviral activity
remained at a maximum, but activity of 2.16a began to drop. At 200 nM, 2.16a was inactive, and
both 2.28 and 2.16e began to lose some activity. EC50 values of 2.16e were ∼50 nM against both
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HSV-1 and -2, which is the most potent anti-HSV activity of a tropolone we have found to date.
Unfortunately, moderate cytotoxicity of 2.16e was also observed.

While increases in potency against HSV were anticipated through additive effects,
surprising effects were observed with pUL15 inhibition. While both a change from an αHT to a
3,7-dHT (2.26 → 2.16a), and from a methyl ester to a biphenyl ketone (2.26 → 2.28) resulted in
a decrease in pUL15 potency, changing both provided an increase in potency (2.26 → 2.16e). One
hypothesis for this change is that the added hydroxyl permits the biphenyl side chain to adopt a
new configuration that would promote new favorable contacts (Figure 2.4A vs. B). In silico
modelling was thus carried out by superimposing the active site of the crystal structure of pUL15C
(PDB id 4IOX)34 to the active site of the crystal structure of HIV RT RNase H bound to manganese
cations and β-thujaplicinol (PDB id 3K2P).35 All computational work was performed by Prof.
Emilio Gallicchio and Rajat Pal. The resulting structure of pUL15C was refined by energy
minimization and simulated annealing using the Impact molecular modeling program.36 The
receptor grid was generated using the default parameters available in the Schrodinger Suite 2016-
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3 with one special adjustment where metal constraints were applied to allow metal–ligand
interaction at the binding site. Glide docking37 were performed with the ligands αHT 2.28 and
3,7-dHT 2.16e. Several binding poses were obtained for the molecule 2.16e, out of which the best
binding pose is shown in Figure 2.4.
This conformation reveals favorable π–cation interaction between the quaternary
ammonium cation of Lys 640 and the phenyl ring π system of the biphenyl group of the ligand.
The biphenyl group is thought to be further stabilized by accommodating within a hydrophobic
groove formed between Lys 640 and Asn 583 with possible hydrophobic interaction with the Leu
636 present inside the groove. Further stabilization could also be achieved through interactions of
the biaryl side chain with Asn 583 through NH–π interactions. These interactions are never
observed in in silico modelling with 2.28. While further studies are needed to understand the
specific mechanism of this increase in activity, these analyses highlight the consequences of the
additional binding modes allowed by 3,7-dHTs, which might also result in greater likelihood of
off-target effects and be a reason for the higher cytotoxicity observed with this class of tropolones.
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2.4. Conclusions
We have developed an oxidopyrylium cycloaddition/ring opening approach for the
synthesis of 3,7-dHTs. This strategy was applied in the synthesis of a prospective biosynthetic
precursor to the natural products puberulonic and puberulic acid. Finally, the new 3,7-dHTs were
tested for antiviral activity against HIV, HBV and HSV. Through these studies we found that
3,7-dHTs are weaker inhibitors than αHTs against HIV RNaseH, revealed 3,7-dimethoxytropolone
as a promising chemotype for HBV-based antiviral development, and demonstrated that 3,7-dHTs
can have greater potency against HSV than analogous αHTs. Furthermore, enzymatic inhibition
studies coupled with preliminary in silico modelling highlight how additional configurations of
3,7-dHTs may manifest themselves in unexpected potency increases, and could also be responsible
for observed cytotoxicity increases.
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2.6. Supplementary Experimental Details
Daniel Schiavone performed some of the synthetic work described in this study. The
biological assays were performed by the Morrison, Tavis, Beutler, and Le Grice labs. Homology
docking studies were carried out by Rajat Pal and Prof. Emilio Gallicchio. All of these
experimental details can be found in the Supporting Information for the publication on which this
chapter is based.S1 This material is provided free of charge by the RSC (http:// http://pubs.rsc.org/).

2.6.1. General Information
All starting materials and reagents were purchased from commercially available sources
and used without further purification, with exception of CH2Cl2, which was purified on a solvent
purification system prior to the reaction. 1H NMR shifts are measured using the solvent residual
peak as the internal standard (CHCl3 δ 7.26, CD3OD δ 3.31, (CD3)2SO δ 2.50), and reported as
follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd =
doublet of doublet, q = quartet, m = multiplet), coupling constant (Hz), and integration. 13C NMR
shifts are measured using the solvent residual peak as the internal standard (CDCl3 δ 77.2, CD3OD
δ 49.0, (CD3)2SO δ 39.5), and reported as chemical shifts. Infrared (IR) spectral bands are
characterized as broad (br), strong (s), medium (m), and weak (w). Microwave reactions were
performed via the Biotage Initiator 2.5. Purification via normal phase column chromatography was
performed on the Biotage Isolera Prime, with Biotage SNAP 10 g or 25 g cartridges, in a solvent
system of ethyl acetate and hexanes. Reverse phase chromatography was performed on the Biotage
Isolera Prime with Biotage SNAP C18 12 g cartridges, in a solvent system of water and acetonitrile
with a 0.05% trifluoroacetic acid additive. Column gradients are measured in terms of column
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volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray ionization (ESI)
technique with a time-of-flight (TOF) mass analyzer.

2.6.2. Synthesis and Characterization of Iodobicycles (2.13a, 2.13b, 2.13e)
General Procedure A. To a solution of salt 2.8aS2 and alkyne (10 equiv) in CH2Cl2 (0.5
M) was added N,N-diisopropylaniline (1.2 equiv). The reaction mixture was subjected to
microwave irradiation at 120 °C for 20 minutes. The reaction mixture was then loaded directly
onto column for chromatography and purified.
General Procedure B. To a solution of dimer 2.17bS2 in CH2Cl2 (0.5 M) was added alkyne
(20 equiv). The reaction was subjected to microwave irradiation at 100 °C for one hour. The
reaction mixture was then loaded directly onto column for chromatography and purified.

Methyl 7-iodo-3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(2.13a).
Procedure A: To a solution of salt 2.8a (185.0 mg, 0.6373 mmol) and methyl 3-iodopropiolate3
(1.3365 g, 6.3734 mmol) in CH2Cl2 (2 mL) was added N,N-diisopropylaniline (148.8
μL, 0.7649 mmol). After microwave irradiation at 120 °C for 20 min, the reaction
mixture was purified by chromatography (Biotage Isolera Prime, 25 g silica gel column, solvent
gradient: 5% EtOAc in hexanes (3 CV); 5-10% EtOAc in hexanes (8 CV); 10-15% EtOAc in
hexanes (10 CV); 15-20% EtOAc in hexanes (10 CV); 20-25% EtOAc in hexanes (10 CV); 2535% EtOAc in hexanes (8 CV)). Product fractions were concentrated to yield 2.13a as a yellow
solid (126.2 mg, 57% yield). Melting point (mp) = 132-135 °C. Rf = 0.25 in 25% EtOAc in
hexanes. IR (thin film, KBr) 2953 (w), 2840 (w), 1711 (s), 1610 (m), 1436 (w), 1379 (w), 1311

62

(m), 1205 (m), 1121 (w), 860 (w), 693 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.06 (s, 1H), 5.03
(s, 1H), 3.84 (s, 3H), 3.55 (s, 3H), 1.75 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 186.9 (s), 163.0
(s), 151.0 (s), 145.1 (s), 119.2 (s), 103.4 (s), 93.8 (s), 88.0 (s), 54.9 (s), 52.3 (s), 21.8 (s). HRMS
(ESI+) m/z calc’d for C11H12IO5+: 350.9724. Found: 350.9752.

Ethyl 7-iodo-3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(2.13b).
Procedure A: To a solution of salt 2.8a (12.47 mg, 0.0430 mmol) and ethyl 3-iodopropiolateS3
(0.0963 g, 0.430 mmol) in CH2Cl2 (0.2 mL) was added N,N-diisopropylaniline (10.03
μL, 0.0516 mmol). After microwave irradiation at 120 °C for 20 min, the reaction
mixture was purified by chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent
gradient: 5% EtOAc in hexanes (3 CV); 5-10% EtOAc in hexanes (8 CV); 10-15% EtOAc in
hexanes (10 CV); 15-20% EtOAc in hexanes (10 CV); 20-25% EtOAc in hexanes (10 CV); 2535% EtOAc in hexanes (8 CV)). Product fractions were concentrated to yield 2.13b as a yellow
oil (15.3 mg, 98% yield). Rf= 0.29 in 25% EtOAc in hexanes. IR (thin film, KBr) 2981 (w), 2936
(w), 1710 (s), 1609 (m), 1448 (w), 1324 (w), 1307 (w), 1259 (m), 1122 (w), 869 (w), 693 (m) cm1

. 1H NMR (200 MHz, CDCl3) δ 6.02 (s, 1H), 4.96 (s, 1H), 4.24 (q, J = 11.1 Hz, 2H), 3.50 (s,

3H), 1.70 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 187.0 (s), 162.6 (s),
150.9 (s), 145.1 (s), 119.3 (s), 103.0 (s), 93.7 (s), 88.0 (s), 61.7 (s), 55.0 (s), 21.7 (s), 14.3 (s).
HRMS (ESI+) m/z calc’d for C12H14IO5+: 364.9880. Found: 364.9886.
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Ethyl 5-(chloromethyl)-7-iodo-3-methoxy-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6carboxylate (2.13c). Procedure B: To a solution of dimer 2.17b (369.4 mg, 1.06
mmol) in CH2Cl2 (2.12 mL) was added ethyl 3-iodopropiolate3 (4.86 g, 21.7
mmol). After microwave irradiation at 100 °C for one hour, the reaction mixture was purified by
chromatography (Biotage Isolera Prime, 50 g silica gel column, solvent gradient: 5% EtOAc in
hexanes (3 CV); 5-10% EtOAc in hexanes (10 CV); 10-20% EtOAc in hexanes (10 CV); 2035% EtOAc in hexanes (8 CV)). Product fractions were concentrated to yield 2.13c as a yellow
oil (596.0 mg, 71% yield). Rf = 0.32 in 25% EtOAc in hexanes. IR (thin film, KBr) 2980 (w),
2936 (w), 2839 (w), 1713 (s), 1613 (s), 1453 (w), 1369 (w), 1311 (m), 1270 (m), 1130 (w), 834
(w), 639 (m) cm-1. 1H NMR (200 MHz, CDCl3) δ 5.99 (s, 1H), 5.13 (s, 1H), 4.44 – 4.22 (m,
2H), 4.26 – 4.00 (dd, 2H), 3.59 (s, 3H), 1.38 (t, J = 7.1 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ
186.1 (s), 162.1 (s), 148.0 (s), 146.1 (s), 114.6 (s), 103.6 (s), 93.8 (s), 89.9 (s), 62.1 (s), 55.2 (s),
44.7 (s), 14.3 (s). HRMS (ESI+) m/z calc’d for C12H12ClINaO5+: 420.9310. Found: 420.9314.

2.6.3. Synthesis and Characterization of Methoxy-8-oxabicyclo[3.2.1]octenes (2.13a, 2.13b,
2.13e)
Methyl 3,7-dimethoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(2.14a).
Procedure: To a solution of bicycle 2.13a (8.6 mg, 0.025 mmol) in methanol (1.23
mL) was added 4-dimethylaminopyridine (3.0 mg, 0.025 mmol). After microwave
irradiation at 120°C for 20 min, the reaction mixture was concentrated under
reduced pressure, taken up in CH2Cl2 and purified by chromatography (Biotage Isolera Prime, 10
g silica gel column, solvent gradient: 5% EtOAc in hexanes (3 CV); 5-35% EtOAc in hexanes (40
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CV)). Product fractions were concentrated to yield 2.14a as a clear oil (5.8 mg, 94% yield). Melting
point (mp) = 138-141 °C. Rf= 0.19 in 25% EtOAc in hexanes. IR (thin film, KBr) 2953 (w), 1696
(s), 1635 (s), 1606 (s), 1449 (w), 1371 (m), 1209 (m), 1112 (s), 834 (w), 723 (m) cm-1. 1H NMR
(200 MHz, CDCl3) δ 6.20 (s, 1H), 5.05 (s, 1H), 3.96 (s, 3H), 3.76 (s, 3H), 3.56 (s, 3H), 1.75 (s,
3H). 13C NMR (100 MHz, CDCl3) δ 188.8 (s), 168.7 (s), 163.8 (s), 145.1 (s), 121.8 (s), 114.2 (s),
86.0 (s), 83.4 (s), 60.7 (s), 54.9 (s), 51.7 (s), 23.0 (s). HRMS (ESI+) m/z calc’d for C12H15O6+:
255.0863. Found: 255.0873.

Ethyl 3,7-dimethoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6-carboxylate
(2.14b).
Procedure: To a solution of bicycle 2.13b (155.1 mg, 0.4259 mmol) in methanol (12 mL) was
added 4-dimethylaminopyridine (139.5 mg, 1.142 mmol). After microwave
irradiation at 120 °C for 20 min, the reaction mixture was purified by
chromatography (Biotage Isolera Prime, 10 g silica gel column, solvent gradient:
5% EtOAc in hexanes (3 CV); 5-35% EtOAc in hexanes (35 CV)). Product fractions were
concentrated to yield 2.14b as a clear oil (73.85 mg, 64% yield). Melting point (mp) = 84-86 °C.
Rf = 0.48 in 50% EtOAc in hexanes. IR (thin film, KBr) 2937 (w), 1709 (s), 1692 (s), 1635 (m),
1604 (m), 1451 (w), 1352 (w), 1241 (w), 1132 (w), 1112 (w), 986 (m), 723 (w) cm-1. 1H NMR
(200 MHz, CDCl3) δ 6.20 (s, 1H), 5.04 (s, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.97 (s, 1H), 3.58 (s,
1H), 1.75 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 188.7 (s), 168.2 (s),
163.2 (s), 144.9 (s), 121.7 (s), 114.2 (s), 85.8 (s), 83.3 (s), 60.5 (s), 60.4 (s), 54.7 (s), 22.9 (s), 14.3
(s). HRMS (ESI+) m/z calc’d for C13H17O6+: 269.1020. Found: 269.1019.
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Ethyl 5-(chloromethyl)-3,7-dimethoxy-2-oxo-8-oxabicyclo[3.2.1]octa-3,6-diene-6carboxylate (2.14c).
Procedure: To a solution of bicycle 2.13c (348.9 mg, 0.8753 mmol) in methanol (43 mL) was
added 4-dimethylaminopyridine (106.9 mg, 0.8753 mmol) in a sealed tube.
After heating at 150 °C for 20 min in a silicon oil bath, the reaction mixture
was purified by chromatography (Biotage Isolera Prime, 25 g silica gel column,
solvent gradient: 5% EtOAc in hexanes (3 CV); 5-35% EtOAc in hexanes (30 CV)). Product
fractions were concentrated to yield 2.14c as a clear oil (161.1 mg, 61% yield). Rf = 0.24 in 25%
EtOAc in hexanes. IR (thin film, KBr) 2980 (w), 1714 (s), 1690 (m), 1637 (m), 1607 (m), 1464
(w), 1380 (w), 1224 (m), 1133 (m), 1072 (w), 983 (w), 725 (w) cm-1. 1H NMR (400 MHz, CDCl3)
δ 6.13 (s, 1H), 5.11 (s, 1H), 4.21 (qd, J = 7.1, 2.8 Hz, 2H), 4.14 – 4.05 (m, 2H), 3.98 (s, 3H), 3.57
(s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 188.0 (s), 168.7 (s), 162.9 (s),
146.2 (s), 117.3 (s), 111.8 (s), 87.9 (s), 83.6 (s), 61.0 (s), 60.9 (s), 55.2 (s), 46.3 (s), 14.5 (s). HRMS
(ESI+) m/z calc’d for C13H16ClO6+: 303.0630. Found: 303.0634.

2.6.4. Synthesis and Characterization of 3,7-Dimethoxytropolones via BCl3
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Methyl 6-hydroxy-4,7-dimethoxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate
(2.15a).
Procedure: To a solution of bicyclic compound 2.14a (6.0 mg, 0.0236 mmol)
in CH2Cl2 (1.69 mL) was added a 1M solution of BCl3 in CH2Cl2 (165.2 μL,
0.1652 mmol). The reaction was allowed to stir at room temperature for 10
minutes before being quenched to pH 7 with pH 7 phosphate buffer. The organic layer was isolated
and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.15a as a red solid (5.8 mg,
97% yield). Melting point (mp) = 93-97 °C. IR (thin film, KBr) 3192 (br), 2950 (w), 1734 (m),
1554 (w), 1459 (w), 1329 (s), 1268 (s), 1217 (s), 1138 (m), 1078 (w), 923 (w), 796 (w). 1H NMR
(400 MHz, CDCl3) δ 6.89 (s, 1H), 3.98 (s, 3H), 3.95 (s, 3H), 3.93 (s, 3H), 2.37 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ 168.6 (s), 167.7 (s), 158.3 (s), 155.2 (s), 150.1 (s), 134.0 (s), 131.1 (s), 119.5
(s), 61.4 (s), 56.8 (s), 52.8 (s), 24.9 (s). HRMS (ESI+) m/z calc’d for C12H14NaO6+: 277.0683.
Found: 277.0689.

Ethyl 6-hydroxy-4,7-dimethoxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate
(2.15b).
Procedure: To a solution of bicyclic compound 2.14b (20.9 mg, 0.0780 mmol) in CH2Cl2 (5.6
mL) was added a 1M solution of BCl3 in CH2Cl2 (546 μL, 0.546 mmol). The
reaction was allowed to stir at room temperature for 10 minutes before being
quenched to pH 7 with pH 7 phosphate buffer. The organic layer was isolated
and the aqueous layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.15b as a yellow oil (16.9 mg,
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81% yield). IR (thin film, KBr) 3734 (w), 2940 (w), 1731 (s), 1553 (s), 1454 (w), 1328 (m), 1267
(m), 1217 (s), 1138 (s), 1017 (w), 901 (w), 669 (s). 1H NMR (200 MHz, CDCl3) δ 6.89 (s, 1H),
4.41 (q, J = 7.1 Hz, 2H), 3.98 (s, 3H), 3.96 (s, 3H), 2.39 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). 13C NMR
(100 MHz, CDCl3) δ 168.3 (s), 167.0 (s), 158.0 (s), 155.1 (s), 149.9 (s), 134.1 (s), 130.9 (s), 119.3
(s), 61.8 (s), 61.2 (s), 56.6 (s), 24.6 (s), 14.2 (s). HRMS (ESI+) m/z calc’d for C13H17O6+:
269.1020. Found: 269.1016.

Ethyl 2-(chloromethyl)-6-hydroxy-4,7-dimethoxy-5-oxocyclohepta-1,3,6-triene-1carboxylate (2.15c).
Procedure: To a solution of 1M BCl3 in CH2Cl2 (80.6 μL, 0.0806 mmol) was added a solution of
bicyclic compound 2.14c (6.1 mg, 0.0202 mmol) in CH2Cl2 (2.88 mL) at 0 °C.
After stirring for 6 minutes, the reaction was slowly added to 6 mL of pH 5
phosphate buffer in a separatory funnel. After shaking, the pH of the aqueous layer was further
adjusted to pH 4 via the gradual addition of an additional 12 mL of pH 5 phosphate buffer. The
organic layer was isolated and the aqueous layer was extracted with CH2Cl2 (5 x 5 mL). Combined
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 2.15c
as a brown oil (4.7 mg, 77% yield) which was immediately taken on to the next step. IR (thin
film, KBr) 2924 (w), 2851 (w), 1731 (s), 1558 (m), 1464 (w), 1335 (m), 1268 (s), 1218 (m), 1135
(w), 1047 (w), 941 (w), 669 (w). 1H NMR (400 MHz, CDCl3) δ 7.07 (s, 1H), 4.48 (s, 2H), 4.45
(q, J = 7.2 Hz, 2H), 4.04 (s, 3H), 3.98 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H).

13

C NMR (100 MHz,

CDCl3) δ 169.4 (s), 166.0 (s), 158.7 (s), 155.8 (s), 149.0 (s), 134.7 (s), 129.1 (s), 117.6 (s), 62.4
(s), 61.3 (s), 56.8 (s), 47.2 (s), 14.2 (s). HRMS (ESI+) m/z calc’d for C13H15ClNaO6+: 325.0449.
Found: 325.0443.
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Ethyl 2-(acetoxymethyl)-6-hydroxy-4,7-dimethoxy-5-oxocyclohepta-1,3,6-triene-1carboxylate (2.15d).
Procedure: To a solution of dimethoxytropolone 2.15c (16.8 mg, 0.055 mmol) in acetic acid (5.55
mL) was added sodium acetate (91.05 mg, 1.11 mmol). The reaction was
allowed to stir at room temperature for 15 hours before being quenched to pH 3
with pH 7 phosphate buffer. The organic layer was isolated and the aqueous
layer was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered,
and concentrated under reduced pressure to yield 2.15d as a brown/yellow oil (14.7 mg, 93%
yield). IR (thin film, KBr) 3734 (w), 2950 (br), 1737 (s), 1558 (w), 1462 (w), 1366 (w), 1333
(w), 1221 (s), 1139 (w), 1073 (w), 669 (w). 1H NMR (400 MHz, CDCl3) δ 7.14 (s, 1H), 5.03 (s,
2H), 4.43 (q, J = 7.1 Hz, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 2.12 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 13C
NMR (100 MHz, CDCl3) δ 170.6 (s), 168.8 (s), 166.2 (s), 158.4 (s), 156.8 (s), 149.8 (s), 135.2
(s), 128.2 (s), 118.0 (s), 66.9 (s), 62.4 (s), 61.5 (s), 57.0 (s), 21.0 (s), 14.3 (s). HRMS (ESI+) m/z
calc’d for C15H18NaO8+: 349.0894. Found: 349.0898.

7-Hydroxy-5,8-dimethoxy-1H-cyclohepta[c]furan-1,6(3H)-dione (2.15e).
Procedure A: A solution of dimethoxytropolone 2.15d (12.9 mg, 0.034 mmol) in 2N aqueous
NaOH (4.78 mL) was allowed to stir at room temperature for 3 hours before
being diluted with 10 mL of CH2Cl2 and quenched to pH 3 with pH 3 phosphate
buffer. The organic layer was isolated and the aqueous layer was extracted with
CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated under
reduced pressure to yield 2.15e as a yellow solid (9.1 mg, 81% yield).
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Procedure B: Dimethoxytropolone 2.15c (4.6 mg, 0.015 mmol) was subjected to reverse phase
column chromatography conditions (Biotage Isolera Prime, SNAP 12g C18 silica gel column,
solvent gradient: 5% acetonitrile in water (3 CV); 5-100% acetonitrile in water (35 CV);
acetonitrile and water each contained 0.05% TFA). Product fractions were concentrated to yield
2.15e as a yellow solid (2.9 mg, 81% yield). Melting point (mp) = 180-184 °C. Rf= 0.36 in 10%
methanol in dichloromethane. IR (thin film, KBr) 3734 (w), 3217 (br), 2945 (w), 1760 (s), 1573
(s), 1457 (w), 1338 (m), 1284 (m), 1122 (w), 1051 (s), 868 (w), 668 (s). 1H NMR (400 MHz,
CDCl3) δ 6.83 (s, 1H), 5.17 (s, 2H), 4.11 (s, 3H), 4.09 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ

171.7 (s), 168.5 (s), 162.4 (s), 154.7 (s), 149.6 (s), 144.6 (s), 119.2 (s), 106.6 (s), 69.8 (s), 62.1 (s),
57.4 (s). HRMS (ESI+) m/z calc’d for C11H11O6+: 239.0550. Found: 239.0558.

2.6.5. Synthesis and Characterization of α-Methoxytropolone via TfOH

Methyl 6-hydroxy-4-methoxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate (2.27).
To a solution of methyl 3-methoxy-5-methyl-2-oxo-8-oxabicyclo[3.2.1]octa3,6-diene-6-carboxylateS4 (484 mg, 2.16 mmol) in CH2Cl2 (22 mL) was added
triflic acid (763 μL, 8.65 mmol). The reaction was allowed to stir for 30 min at
rt before quenching with pH 7 phosphate buffer. The reaction mixture was then extracted with
CH2Cl2 (3 x 20 mL), and the combined organics were dried over Na2SO4, filtered, and concentrated
under reduced pressure to yield 2.27 as a brown solid (377 mg, 78% yield). Product can be further
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purified via crystallization in MeOH to yield a yellow solid (233 mg, 48% yield). Melting point
(mp) = 168-171 °C. IR (thin film, KBr) 3251 (br), 2918 (w), 2848 (w), 1717 (s), 1554 (m), 1483
(w), 1457 (m), 1335 (s), 1297 (m), 1220 (s), 1139 (w), 1053 (s), 907 (w), 788 (m) cm -1. 1H NMR
(400 MHz, CDCl3) δ 7.56 (s, 1H), 6.99 (s, 1H), 3.99 (s, 3H), 3.89 (s, 3H), 2.53 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ 171.0, 169.1, 159.6, 158.3, 137.4, 131.5, 121.5, 117.4, 56.6, 52.9, 26.0.
HRMS (ESI+) m/z calc’d for C11H13O5+: 225.0757. Found: 225.0753.

2.6.6. Synthesis and Characterization of 3,7-Dihydroxytropolones

Methyl 4,6,7-trihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate (2.16a).
Procedure: To dimethoxytropolone 2.15a (3.3 mg, 0.0130 mmol) was added 145 μL of 33%
HBr/AcOH. The reaction was heated to reflux at 120 °C for 35 minutes before
being quenched to pH 4 with pH 7 phosphate buffer. The organic layer was
isolated and the aqueous later was extracted with CH2Cl2 (5 x 10 mL). Combined
organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 2.16a
as a red/brown solid (1.6 mg, 55%). Melting point (mp) = 131-135 °C. IR (thin film, KBr) 3198
(br), 2925 (w), 1733 (s), 1586 (w), 1525 (m), 1431 (s), 1325 (s), 1201 (s), 1057 (w), 878 (w), 796
(w). 1H NMR (400 MHz, CD3OD) δ 7.00 (s, 1H), 3.91 (s, 3H), 2.32 (s, 3H). 13C NMR (100 MHz,
CDCl3) δ 167.2 (s), 157.3 (s), 154.5 (s), 153.4 (s), 152.3 (s), 136.8 (s), 125.0 (s), 120.8 (s), 52.1
(s), 24.7 (s). HRMS (ESI+) m/z calc’d for C10H11O6+: 227.0550. Found: 227.0556.
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Ethyl 4,6,7-trihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylate (2.16b).
Procedure: To dimethoxytropolone 2.15b (15.5 mg, 0.0578 mmol) was added 682 μL of 33%
HBr/AcOH in a sealed 0.5-2.0 mL sealed microwave vessel. The reaction was
heated to reflux at 120 °C for 45 minutes in a silicon oil bath before being
quenched to pH 4 with pH 7 phosphate buffer. The organic layer was isolated and the aqueous
later was extracted with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered,
and concentrated under reduced pressure to yield 2.16b as a red/brown oil (12.0 mg, 87%). IR
(thin film, KBr) 3210 (br), 2929 (w), 1730 (s), 1581 (w), 1445 (w), 1326 (w), 1193 (s), 1056 (m),
1012 (w), 860 (w), 779 (w) cm-1. 1H NMR (400 MHz, CD3OD) δ 7.02 (s, 1H), 4.39 (q, J = 6.8
Hz, 2H), 2.33 (s, 3H), 1.37 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CD3OD) δ 169.3 (s), 158.7
(s), 157.5 (s), 157.4 (s), 153.2 (s), 137.0 (s), 126.9 (s), 121.0 (s), 62.8 (s), 24.4 (s), 14.4 (s). HRMS
(ESI+) m/z calc’d for C11H12NaO6+: 263.0526. Found: 263.0528.

2,3,7-Trihydroxy-5-methylcyclohepta-2,4,6-trien-1-one (2.16c).
Procedure: To dimethoxytropolone 2.15a (6.5 mg, 0.0256 mmol) was added 4.6 μL (10 equiv.)
of water and 284 μL of 33% HBr/AcOH in a sealed 0.5-2.0 mL sealed microwave vessel. The
reaction was heated to reflux at 120 °C for 35 minutes. The membrane of the sealed
vessel was punctured with an 18G needle to release gas buildup approximately 10
minutes after subjecting reaction to heat. Upon completion, the reaction was quenched to pH 4
with pH 7 phosphate buffer. The organic layer was isolated and the aqueous later was extracted
with CH2Cl2 (5 x 10 mL). Combined organics were dried over Na2SO4, filtered, and concentrated
under reduced pressure to yield 2.16c as a red/brown oil (1.8 mg, 42%). IR (thin film, KBr) 3509
(br), 3218 (br), 2918 (m), 1591 (w), 1517 (m), 1434 (s), 1394 (w), 1339 (w), 1199 (s), 1092 (m),
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1068 (w), 668 (m) cm-1. 1H NMR (400 MHz, CD3OD) δ 7.01 (s, 2H), 2.40 (s, 3H).

13

C NMR

(100 MHz, CD3OD) δ 158.2 (s), 156.6 (s), 141.2 (s), 120.3 (s), 27.0 (s). HRMS (ESI+) m/z calc’d
for C8H9O4+: 169.0495. Found: 169.0492.

5,7,8-Trihydroxy-1H-cyclohepta[c]furan-1,6(3H)-dione (2.16d).
Procedure: To dimethoxytropolone 2.15e (10.0 mg, 0.042 mmol) was added 453 μL of 33%
HBr/AcOH in a sealed 0.5-2.0 mL sealed microwave vessel. The reaction was
heated to reflux in a silicon oil bath at 120 °C for 30 minutes before being
quenched to pH 1.5 with pH 5 phosphate buffer. The organic layer was isolated
and the aqueous layer was extracted with CH2Cl2 (3 x 2 mL). Combined organics were dried over
Na2SO4, filtered, and concentrated under reduced pressure to yield 2.16d as a yellow solid (5.0
mg, 57%). IR (thin film, KBr) 3502 (br), 3215 (br), 2962 (w), 2918 (s), 2849 (m), 1747 (m), 1622
(w), 1517 (w), 1260 (s), 1096 (m), 1022 (s), 799 (s) cm-1. 1H NMR (400 MHz, DMSO-d6) δ 6.83
(s, 1H), 5.17 (s, 2H). 13C NMR (150 MHz, DMSO-d6) δ 171.0 (s), 164.7 (s), 159.9 (s), 154.3 (s),
150.9 (s), 149.1 (s), 109.8 (s), 105.1 (s), 69.7 (s). HRMS (ESI+) m/z calc’d for C9H7O6+: 211.0237.
Found: 211.0231.
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2.6.7. NMR Spectra of Synthesized Compounds
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Chapter III
Studies on Configurational Stability of Troplone-Amide Aryl-CO Bonds
3.1 Introduction
A fundamental goal of drug discovery is to develop
safe and effective compounds with specificity towards their
intended disease targets. In order to achieve this objective, it
is crucial to consider the three-dimensional properties of
drugs. One such characteristic is the handedness, or chirality,
of a molecule since different spatial orientations of drugs with
identical connectivity can have drastically differing effects in
the body. While chirality is typically thought of in terms of
asymmetry about a single atom or point, axial chirality
(Figure 3.1) is a critically understudied form of chirality in
which the spatial arrangement of substituents about an axis
renders the molecule non-superimposable on its mirror image.1 Atropisomerism arises from restricted
rotation about this axis, thus allowing for isolatable enantiomers. This type of isomerism is often
exemplified by the biaryl scaffold where restricted rotation about the stereogenic CAr-CAr axis is
responsible for the presence of enantiomers (Figure 3.1C). Separable atropisomers can generally be
observed if the energetic barrier to rotation (ΔG‡) about the chiral axis is > 22 kcal/mol,
corresponding to a half-life to racemization of >1000 seconds at room temperature.2 It is an issue of
current interest in the development of ligands,3 molecular devices,4 and pharmaceutical drugs.5
Atropisomerism is perhaps most widely appreciated within the field of synthetic organic
chemistry as the source of chirality in numerous chiral biaryl ligands for asymmetric catalysis.
Axially chiral bidentate ligands, such as BINAP, are most famously recognized for their use in
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Noyori’s asymmetric hydrogenation work on olefins and carbonyls (Figure 3.2A) for which he
was awarded the 2001 Nobel Prize.6 BINAP ligands have also been used extensively in
atropselective cross-couplings.7 The importance of atropisomerism can also be found in other areas
such as unidirectional molecular devices8 and switches,9 the development of which won Feringa
the 2016 Nobel Prize (Figure 3.2B).

While numerous axially chiral drugs are commercially available, many exist as rapidly
interconverting atropisomers with only one enantiomer possessing the desired activity.10
Single-enantiomer drugs have long been considered of paramount importance; perhaps most
infamously, the antiemetic racemate thalidomide caused devastating birth defects in more than
10,000 babies in the 1950s owing to toxicity associated with the (S)-enantiomer as well as facile in
vivo racemization.11 Consequently, the development of efficient synthetic strategies to access single
enantiomers is a major theme of modern synthetic organic chemistry.
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The thalidomide tragedy was not a standalone incident. Enantiomers of numerous drugs
possessing point chirality have been shown to demonstrate drastically differing effects in the body.12
Similarly, it has been found that the presence of the opposite atropisomer can result in off-target
binding, and preorganizing (or locking) a freely rotating axis into the relevant configuration can
increase target selectivity.10,13 Single-atropisomer drugs are available (Figure 3.3), though their
locked configuration is rarely deliberate. For instance, drugs such as Viagra (sildenafil) and Imatinib,
while not displaying obvious chirality, will bind to their receptors in an enantiospecific form.

Meanwhile, configurationally stable scaffolds such as colchicine,14 gossypol15 and vancomycin16
exist, but are frequently discovered as natural products and their high rotational barriers are as such
not a design element. This is important because, as in the case of thalidomide, crucial differences in
biology have been observed between separated atropisomers.10,13 (+)-Telenzepine, for example, is
500 times more potent than (–)-Telenzepine,17 while the S atropisomer of colchicine is the only active
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form.14 The design of single-atropisomer drugs would therefore represent a paradigm shift away
from point chirality towards axial chirality for drug discovery. Two major hurdles have impeded
these efforts thus far: 1) Exceptionally high rotational barriers (>28 kcal/mol) in vivo are needed to
ensure long-term biological configurational stability,18 and 2) there exists a dearth of efficient
synthetic methods to access such molecules.
The following chapter will describe a solution to these challenges in the study of the
rotational barriers and physical properties of troponoids. Owing to their ring size and increased
bond angles, troponoids are predicted to
have

exceptionally

high

rotational

barriers (Scheme 3.1). They also have
exceptional bioactivity (see Chapters 1
and 2). The combination of these
properties

makes

troponoids

ideal

candidates for the development of singleatropisomer drugs. However, they have
historically represented a significant synthetic challenge; as such, there exists a scarcity of troponoid
structure-function studies, with most current synthetic methods stifled by an inability to functionalize
more than one position on the ring. Thus, the remainder of this chapter will discuss efforts to leverage
ongoing synthetic studies in the Murelli lab towards the synthesis of configurationally stable troponoids.

3.2. Discovery of α-Hydroxytropolone Atropisomerism
3.2.1. 1H-NMR Profiles of a Troponoid and Benzenoid Thiazolidine
As part of our ongoing medicinal chemistry studies, we synthesized thiazolidine
α-hydroxytropone 3.4 via the oxidopyrylium cycloaddition/ring-opening route described in
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Chapters 1 and 2 towards carboxylic acid 3.3 (Figure 3.4).19 Upon observing a remarkable degree
of atropdiastereoselectivity by 1H-NMR, we became curious as to whether the analogous
benzenoid would demonstrate similar properties at room temperature and thus carried out a similar
amide coupling on benzoic acid 3.5. The resulting room temperature 1H-NMRs displayed very
different profiles with the troponoid (Figure 3.4C, bottom, red) showing a clean set of AB quartets
while the analogous thiazolidine signal on the benzenoid (Figure 3.4C, top, blue) presents as a set
of singlets.

3.2.2. Experimental Calculation of Thiazolidine Rotational Barriers
The reduced symmetry of the amide functionality in thiazolidines 3.4 and 3.6 enabled us
to obtain kinetic parameters for Ar-CO atropisomerization via variable temperature 1H-NMR
spectroscopy (Figure 3.5). Two moieties were investigated: the methylene in between the N and
S (purple orb, Figure 3.4), and the methylene on the other side of the N (blue orb, Figure 3.4; see
Supporting Information for details). The amide rotamers remained resolved over the course of
these experiments, and we therefore were able to obtain rotational barrier measurements for each
of the E/Z amide isomers. Benzenoid 3.6 was found to exist in rapid atropisomeric equilibrium at
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25 °C, showing a single set of peaks for each E/Z amide rotamer with no atropdiastereotopic
splitting. Therefore, the coalescence point of the benzenoid was met by cooling the sample down,
while the troponoid required heating in order to observe coalescence. From this alone, a clear
qualitative conclusion is evident: the benzenoid signals coalesce well before the troponoid signals
(see Figure 3.5 and the Supporting Information). This pattern is evident across all signals
belonging to both sets of molecules except for the most downfield methylene peak corresponding
to the Z rotamer of the benzenoid. Initially, it was suspected that this rotamer may have a higher
C-C rotational barrier; however, given that the other signals all coalesce, it can be concluded that
the chemical shifts of the Z rotamers’ atropdiastereotopic protons are coincidentally equivalent.
Since E/Z amide isomerization occurs at a significantly higher barrier than C-C
isomerization, the ΔG‡ between
the two atropisomeric forms (aS
and

aR)

in

determined

solution
by

were

lineshape

simulation of VT-NMR spectra
using

iNMR

software.20

These

modeling
lineshape

simulations were based on the
experimental spectra obtained
for

both

compounds,

specifically on the chemical
shifts and coupling constants,
and gave a rate constant (k) for each temperature. This data was converted into a barrier to rotation
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at a given temperature by plotting 1/T vs ln(k/T) and performing an Eyring plot (see Supporting
Information).21 This plot gives a straight line, the slope of which gives the enthalpy of rotation
(ΔH‡) and the y-intercept of which gives the entropy of rotation (ΔS‡). Inserting these values into
Gibbs’ equation for free energy gives the rotational energy (ΔG‡). In each case, the linear
regression performed was obtained from a set of 5 data points with correlation coefficients between
0.9855 and 0.9984, demonstrating a high degree of linearity for the data obtained.
In the case of the benzenoid, C-N kinetic parameters were also analyzed by heating the
sample in DMSO-d6 (Figure 3.5A). Troponoid C-N rotation remained too high in energy to be
measurable within the temperature limitations of the NMR, but benzenoid C-N isomerization could
be observed (ΔG‡ = 16.4 kcal/mol, see Supporting Information for details). This alone speaks to
the levels of ancillary rigidity that can be provided by restricted C-C rotation in troponoids. All in
all, the difference in rotational barriers between the 6- and 7-membered substrates is considerably
large. To gain a better understanding of the physical basis of these differences, we turned to
molecular modeling to assess the barriers of a small library of benzenoid and troponoid derivatives.

3.3. Computational Modeling of Troponoids
3.3.1. Preliminary Substrate Scope
This work was performed in collaboration with Dr. Anthony Metrano at Yale University
and the approach used in these studies had been optimized for benzenoids22 and quinazolinones.23
This work represents the first instance of a head-to-head comparison of benzenoid and troponoid
side-chain rotational barriers via computational modeling, and one of the first extensive examples
of troponoid rotational energy modeling entirely.24 Rotational barriers about the aryl/amide axis
were performed using the OMEGA and GRACE supercomputer clusters provided by the Yale

113

University Faculty of Arts and Sciences High Performance Computing Center. All calculations
were carried out using the Gaussian 09 suite.25,26 Ground state geometries were first optimized
using density functional theory (DFT) at the B3LYP/6-31+G(d,p) level of theory.27 Harmonic
vibrational frequencies were simultaneously calculated. The optimized structures were then used as
foundations for a restricted torsional potential energy scan (PES) at the same level of theory. The
scan was conducted by first defining the dihedral angle in question (CO-CAr) as the constrained
coordinate and performing a scan of that angle through 360° in 10° increments using the same
method and basis set.
The resulting torsional profile was subsequently used as a starting point from which to
narrow in on the single-point energies. The geometries of the scan maxima (transition states) were
subjected to further optimization using B3LYP/6-31+G(d,p). The frozen single-point output
geometries of these calculations, as well as the stationary ground state points on the torsional energy
profile, were subjected to further optimization with no dihedral restrictions in place at the M06-2X/6311++G(2d,3p) level of theory and basis set.28 All calculations were performed at the gas phase. The
output from these calculations were inspected, and in the case of the transition states, the imaginary
frequency was verified as a vibration along the reaction coordinate of interest. The M06-2X total
electronic energies were converted to Gibbs free energies and the barrier height ΔG‡ values were
converted to kcal/mol from Hartrees using a conversion factor of 627.509 a.u. = 1 kcal/mol. The
Arrhenius equation was then used to calculate rate constants for each barrier of the rotation (k1 and
k2). These rate constants were then added to provide an observed rate constant, kobs. This value was
used to calculate the observed barrier, ΔG‡(obs) using the following equation:
Δ𝐺 ‡ (𝑜𝑏𝑠) = −𝑅𝑇 ∗ 𝑙𝑛
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𝑘𝐵 𝑇
ℎ𝑘𝑜𝑏𝑠

(Eq. 3.1)

where R is the ideal gas constant [1.99 x 10-3 kcal/(molK)], T is the temperature in Kelvin, kB is the
Boltzmann constant [1.38 x 10-23 (m2kg)/(s2K)], and h is Planck’s constant [6.63 x 10-34 (m2kg)/(s2)].
This approach was used to calculate rotational barriers for a series of methoxytropolones
and their corresponding benzenoids. In order to minimize complicating factors such as
tautomerization, we chose to focus on methoxytropolones as they are key intermediates in our
synthetic route towards αHTs with only two possible tautomers. Given previous 2D-NMR29 and
x-ray crystallographic30 evidence that the 7-methoxytropolone is the predominating tautomer, all
troponoids were modeled in this form. These results are summarized in Table 3.1.

During the course of these studies, a remarkable trend was observed: the troponoid substrates
consistently displayed drastically increased rotational barriers when compared to their analogous
benzenoids, with observed increases in half-life to racemization of up to 4 orders of magnitude.
While we had anticipated that the decreased external bond angles of the troponoids would result in
increased rotational barriers, the extent to which this effect was observed was particularly dramatic.
Interestingly, the methyl ester (entry 4, Table 3.1) represents the sole exception to this trend - the
transition state in the benzenoid isomerization pathway is orthogonal as opposed to co-planar, thus
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losing the stabilizing effect of extended conjugation in the transition state. Nonetheless, in the
interest of studying a biologically relevant system, we subsequently modeled thiazolidines 3.4/3.6.

3.3.2. Computational Modeling of Benzenoid and Troponoid Thiazolidines
The asymmetry of the amide moiety resulted in several complicating factors. The presence
of non-degenerate E/Z amide rotamers gave rise to 4 unique ground states, each proceeding
through one of three pathways to interconversion: rotation about the C-C axis, C-N axis, or a
concerted mechanism (see Figure 3.6). Independent C-N bond rotation was computed to proceed
through one of two degenerate transition states, depending on the direction of rotation: when the
thiazolidine sulfur atom is proximal to the methyl group, the energy is increased and independent
C-C rotation is not possible.
Additionally, computations assessing the energy of C-C bond rotation lead to a concerted,31
simultaneous rotation about the atropisomeric C-C axis and C-N axis.22b Compared to independent
C-N rotation, which is a significantly higher energy process, this concerted C-N/C-C rotation
represents the lowest energy pathway to amide isomerization (Figure 3.6). These computational
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results imply that E/Z isomerization for a given enantiomer most likely involves first, a concerted
rotation of the C-C and C-N axes, and second, an independent C-C rotation. Regardless, the lowest
energy atropisomeric racemization pathway was found to proceed via independent C-C rotation,
as observed by 1H-NMR. The presence of DMSO in the troponoid experimental measurement
likely accounts for the small differences between its calculated and experimental barriers. Even
so, the benzenoid computed barriers were found to be in very good accord with the experimentally
determined value. This data is summarized in Table 3.2.

Ultimately, the differences in rotational barriers between the 6- and 7-membered substrates
are notably large. We thus became curious if there was any way we could further exacerbate these
differences, while simultaneously synthesizing high-rotational barrier troponoids. Given the vast
literature precedence for employing halogenation on 6-membered homologs as a means of
achieving configurational stability,22,23 we thought this seemed like feasible chemistry we could
undertake on a troponoid. Prior to this synthetic work, we modeled brominated variants of the
7-methoxytropolones shown in Table 3.1 to see if we could verify this hypothesis.
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3.3.3. Modeling of Brominated 7-Methoxytroponoids and Benzenoids
The same approach as described in Section 3.2.1 was utilized in the rotational barrier
calculations on the brominated benzenoids and troponoids; the results are summarized in Table
3.3.

As expected, the brominated troponoids maintained dramatically higher barriers with
respect to their respective benzenoids. This disparity is well exemplified by the piperidinyl-based
scaffolds 3.18 and 3.23 (entry 2, Table 3.3), in which the half-life of racemization changes from 1.4
hours to over 200 years. Even more astounding, however, is the difference between the brominated
diisopropyl-based scaffolds 3.19 and 3.24 (entry 3), where the half-life of racemization increases
from ~2 days to 7593 years!
This intriguing disparity made us curious about the rotational energies of brominated but less
sterically demanding substrates such as esters and ketones, which we subsequently modeled. As
expected, they demonstrated low barriers to racemization even post-bromination, although the
troponoids remained consistently higher. In all cases excluding R1 = OMe and R2 = R3 = H (entry
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1, Table 3.1), the pathway of isomerization involves geared rotation about the CAr-CO and R1-CO
axes in both the troponoids and the benzenoids.
From this aggregate data, two key trends can be observed (Figure 3.7). Within the brominated
molecules (R3 = Br), the troponoids were all computed at ~8 kcal/mol higher in energy than their
analogous benzenoids. As well, the difference in rotational energies between non-brominated and
brominated substrates is considerably higher for the tropolones than for the respective benzenoids (15.7
vs 11.7 kcal/mol, where a bond rotation energy of >28 kcal/mol is necessary for configurational
stability).18 As it appears that troponoids are more sensitive to structural changes than their respective
benzenoid systems, our synthetic method towards αHTs could be utilized in the development of highly
rigid atropisomeric drugs with critical implications on our ongoing medicinal chemistry studies.
35
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An eventual aim of this work is to develop single-atropisomer αHT derivatives for
medicinal chemistry pursuits. The calculated troponoids are only a demethylation away from
containing the active pharmacophore, and furthermore, contain an extremely useful handle for
cross-coupling and further derivatization. As our standard demethylation conditions are run in
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refluxing hydrobromic acid, and cross-coupling reactions will likely need to be run at elevated
temperatures, we computed rotational barriers for 3.8 and 3.18 at 125 °C (entries 6 and 7, Table
3.3). The barriers increase slightly at elevated temperatures due to increases in the entropic
component of ΔG‡. However, the half-life does decrease substantially. Thus, the temperatures of
future functionalization reactions will need to be kept in mind.
While these results are highly promising, the calculations are not without limitations. The
approach employed was developed for benzenoids22a and quinazolinones,23a and troponoid
characteristics such as tautomerization,32 puckering,33 and electronic properties such as decreased
aromaticity34 can all influence the actual rotational barrier. Furthermore, even small changes in highvalue free energy calculations can produce large rate effects since rate increases exponentially with ΔG.
With this in mind, we modeled the tautomeric forms of 3.8 and 3.18 (3.8b and 3.18b; entries 8 and 9,
Table 3.3) and found that while the two sets of tautomers have nearly identical respective ground state
energies, the second tautomer enantiomerizes through a considerably higher energy pathway (i.e. 3.18
versus 3.18b, entries 2 versus 9, Table 3.3). This may result from repulsion between the carbonyl oxygen
(which has anionic character resulting from troponoid aromaticity, requiring a formal positive charge on
the carbonyl carbon) and the adjacent bromide. Regardless, we reasoned that racemization occurs
predominantly via the first tautomer, which was the same tautomeric form assessed in all of the
computations described above. We then set about confirming these higher rotational barriers
experimentally.

3.4. Synthesis of Bromotropolones: Experimental Confirmation of Higher Barrier Molecules
Bromotroponoids had previously shown utility in some of our own medicinal chemistry
pursuits.35 In several cases, adding a halogen has increased the bioactivity over the parent scaffold,
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and the added electron density provided by the halogens can yield higher quality x-ray crystal
structures by increasing the atomic scattering factor.36 In addition, there are many examples in the
literature of halogens increasing barriers to rotation about an adjacent axis22,23,37 with biomedical
benefits.38 For example, this strategy has been leveraged by the Gustafson lab in the synthesis of
a series of chlorinated kinase inhibitors, where it was found that the different atropisomers had
drastically different biological activity (Scheme 3.2).39 Given these factors, we set out to develop
a synthetic route to halotropolones. Early synthetic efforts utilizing bromomethylpropiolate 3.30
lead to αHT 3.32, which has subsequently proven to be a highly valuable intermediate in a variety
of pursuits.40
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As this ester was not computationally predicted to be configurationally stable, we turned
our attention to piperidinyl amide 3.18. This molecule was first synthesized via an oxidopyrylium
cycloaddition using bromoalkyne 3.34b to access bicyclic intermediate 3.35b, which was
subsequently converted to methoxytropolone 3.18 via a triflic acid-mediated ring opening.
Unfortunately, attempts to demethylate the analogous iodo-based methyl ester methoxytropolone
lead to a mixture of products, while the strong lachrymator properties of bromopropiolates posed
technical challenges. To overcome these difficulties, we developed a regioselective electrophilic
bromination that allowed us to convert tropolones directly to bromotropolones (i.e. 3.8 → 3.18,
Scheme 3.3).

3.5. Experimental Validation of Bromotropolone Rotational Barriers
In order to obtain experimental rotational barrier measurements of 3.18, we attempted to
separate the enantiomers via HPLC. Unfortunately, while we were able to obtain analytical
chromatographic conditions to resolve the atropisomers of 3.18, attempts to separate the
enantiomers via preparatory scale HPLC proved problematic owing to the low separation factor of
the peaks.
Instead, we sought to obtain enantioenriched material and monitor thermal racemization,
and so we turned our attention to a dynamic, kinetic peptide-catalyzed atropselective halogenation
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strategy developed by the Miller group (i.e. 3.36a → 3.36b, Scheme 3.4A).22a This approach, first
published in Science in 2010,41 exploits the differences in rotational barriers around a chiral axis
before and after bromination and has been applied to biaryls,41,42 quinazolinones,23a and
benzamides.22a To the best of our knowledge, the only atropselective halogenation on a non-phenolic
system was reported in 2016 towards the groundbreaking asymmetric total synthesis of natural
product marinopyrrole A.43 Unfortunately, this route suffered from low selectivity (11% ee); as such,
Miller’s work represents the current state-of-the-art in atropselective halogenation.
The selectivity of Miller’s work, delivered by the peptide catalyst, is provided through a
hydrogen bond network involving an H-bond donor and acceptor flanking the bromination site on
the axially chiral substrate (see Scheme 3.4). As these features are shared by our troponoid scaffolds,
we became intrigued by the possibility of using this method to halogenate troponoids. Thus, we
initiated a collaboration with the Miller group to develop the first published method for catalytic,
atropselective troponoid synthesis. After some optimization (see Chapter 4 for details), we were able
to identify conditions that provided methoxytropolone 3.18 in 75:25 er via catalyst 3.38. While
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efforts remain underway to increase selectivity, this method proved sufficient for obtaining optically
enriched material for measuring experimental rotational energy barriers.

3.5.1. Determination of Rotational Barrier via Thermal Erosion of Enantiopurity
Racemization studies were performed on 3.18 to obtain its barrier to rotation (Figure
3.8).44 A solution (5.6 mM) of 3.18 (50% ee) in triethylene glycol dimethyl ether (triglyme) was
heated in an oil bath at 145 °C. The enantiomeric ratio was measured by reversed phase chiral
HPLC at time points spanning 2 to 60 minutes. Plots of ee versus time, and of ln(1/ee) versus time
resulted in the respective graphs shown below. Using the slope of these lines and the Eyring
equation, the free activation energy was determined and it was found that 3.18 has a barrier to
rotation of 30.1 kcal/mol at 145 °C. Owing presumably to hydrogen bonding effects with the glyme
solvent, the experimental value is slightly lower than that computed at 145 °C (ΔG‡ = 32.7
kcal/mol), though certainly within the range of experimental error. Thus, experimental data clearly
indicates that 3.18 has exceptionally high configurational stability and helps further illustrate the
role that troponoids could play in designing molecules with enhanced conformational rigidity.
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3.6. Resolution of a Single-Atropisomer α-Hydroxytropolone
Given the generally high rotational barriers of troponoids, we became interested in
leveraging this quality towards developing molecules with biomedical utility. Recently, there has
been a growing appreciation for atropisomerism in drug development and for designing
atropisomerism in order to increase target specificity. Given the wealth of biological targets known
to be accessible to αHTs, we decided to resolve optically pure αHTs for future biological testing.
Simple demethylation using our standard conditions (refluxing HBr/AcOH) was effective for the
piperidinyl substrate. The enantiomers were successfully resolved via preparatory CSP-HPLC to
a high degree of optical purity and their relative stereochemistry was determined (MPLC
Chiralflash IC: Ent-1: (+)-3.39, >99:1 er; Ent-2: (-)-3.39, 97:3 er), setting the stage for future
biological testing. Additionally, (-)-3.39 was found to be stable at physiological conditions (in a
4.4 mM solution of PBS buffer, pH 7.4, at 37 °C) for 24 hours with no loss of enantioenrichment
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observed over this timeframe, further demonstrating the potential value of rotationally restricted
troponoids within biological applications.

3.7. Optical Assignment of Bromotroponoid Enantiomers
With optical rotation measurements of enantiopure [(+)-3.39] and enantioenriched
[(-)-3.39] in hand, we set about determining the relative stereochemistry of 3.18 in order to
determine the preference of peptide 3.38 for formation of (+) or (-) product. To this end, we
subjected enantioenriched 3.18 to our demethylation conditions.45 With a computed t1/2 of ~7 hours
at the demethylation temperature of 125 °C, we anticipated seeing erosion of enantioenrichment –
though not full racemization – within 30 minutes. Thus, we subjected 3.18 to these conditions, and
gratifyingly found some retention of enantioenrichment (50% ee → 28% ee). From the HPLC trace
of enantioenriched 3.39 as well as analogy to a previously reported atropselective halogenation
(3.36a → 3.36b vs. 3.8 → 3.18, Scheme 3.12),22a we were able to infer that peptide 3.38 favors
formation of the second-eluting (-) enantiomer (Figure 3.9). Depending on the relative
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bioactivities of (+)- and (-)-3.39, future atropselective synthetic efforts towards single-enantiomer
troponoids may benefit from this knowledge.

3.8. Conclusions
Atropisomerism has an established and valuable role in a variety of scientific pursuits and
troponoids possess unique structural properties resulting in increased rotational barriers that are of
high interest in related studies. As such, computational and experimental rotational barriers
measured on tropamides revealed that troponoid-based chiral axes have substantially higher
rotational barrier measurements when compared to analogous benzenoid systems. Critical to the
achievement of this discovery was the computational modeling of a library of axially chiral aryl
systems, as well as the development of a catalytic atropselective halogenation on a novel troponoid
substrate. Optimization of this reaction will allow us to aid in an emerging paradigm shift towards
studying designed and restricted axial chirality in drug development.
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3.10. Supplementary Experimental Details
Computational studies on the methoxytropolones and analogous benzenoids were
performed in collaboration with Dr. Anthony Metrano. Elizabeth Stone and Dr. Golo Storch
performed the computational studies on the thiazolidines. All of these computational details can
be found in the Supporting Information for this manuscript. S1

3.10.1. General Information
All starting materials and reagents were purchased from commercially available sources
and used without further purification, with exception of CH 2Cl2, which was purified on a solvent
purification system prior to the reaction. All reactions were performed in oven- or flame-dried
glassware. 1H-NMR shifts are measured using the solvent residual peak as the internal standard
(CHCl3δ7.26, MeOH δ 3.31, CH2Cl2 δ 5.32, DMSO δ 2.50), and reported as follows: chemical
shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet,
q = quartet, m = multiplet, dd = doublet of doublets, ddd = doublet of doublet of doublets, dt =
doublet of triplets, dq = doublet of quartet, ABq = AB quartet), coupling constant (Hz), and
integration. 13C NMR shifts are measured using the solvent residual peak as the internal standard
(CHCl3 δ77.2, MeOH δ 49.0, DMSO δ 39.5), and reported as chemical shifts. Infrared (IR)
spectral bands are characterized as broad (br), strong (s), medium (m), and weak (w). Microwave
reactions were performed via the Biotage Initiator 2.5. Analytical thin-layer chromatography
(TLC) was performed using Silica Gel 60 Å F254 pre-coated plates (0.25 mm thickness). TLC R f
values are reported, with visualization accomplished by irradiation with a UV lamp or
appropriate TLC stain. Purification via normal phase column chromatography was performed on
the Biotage Isolera Prime, with Biotage SNAP 10g or 25g cartridges, in a solvent system of ethyl
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acetate and hexanes. Reversed phase chromatography was performed on the Biotage Isolera
Prime with Biotage SNAP C18 12 g cartridges, in a solvent system of water and acetonitrile with
a 0.05% trifluoroacetic acid additive. Column gradients are measured in terms of column
volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray ionization
(ESI) technique with a time-of-flight (TOF) mass analyzer. Commercially available
dibromodimethylhydantoin (DBDMH) and N-bromosuccinimide (NBS) were purified by
recrystallization from hot water. Optical rotations were recorded on a Perkin-Elmer Polarimeter
341 at the sodium D line (1.0 dm path length). Reverse-phase HPLC analysis was conducted
with an Agilent 1100 series instrument equipped with a diode array detector (λ = 265 nm) and
columns (chiral supports) from Daicel Chemical Industries (Chiralpak IA and Chiralpak IC) at
ambient temperature. Reverse phase preparatory HPLC separation was performed on the Biotage
Isolera Prime with a 30 x 100 mm (20 µm particle size) Chiralflash IC column.

3.10.2. Synthesis and characterization of 3-bromo-1-(piperidin-1-yl)prop-2-yn-1-one (3.34b)

Procedure: To a solution of 1-(piperidin-1-yl)prop-2-yn-1-one 3.34aS2 (563.9 mg, 4.11 mmol)
in acetone (8.22 mL) was added N-bromosuccinimide (804.6 mg, 4.52
mmol). After stirring for 5 minutes, silver nitrate (69.63 mg, 0.411 mmol)
was added slowly ambient temperature. The reaction was allowed to stir for
1.5 hours in the dark before being quenched by 10 mL of water. The reaction mixture was added
to a separatory funnel containing 20 mL of CH 2Cl2. The organic layer was isolated and the
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aqueous layer was extracted with CH2Cl2 (3 x 10 mL). Combined organics were extracted with
20 mL of water, 20 mL of saturated sodium bicarbonate solution, and 20 mL of aqueous sodium
chloride. Combined organics were dried over Na2SO4, filtered, and concentrated under reduced
pressure to yield 3.34b as a light yellow solid (774.6 mg, 87% yield). Melting point (mp) =
54-56 °C. Rf= 0.35 in 25% EtOAc in hexanes. IR (thin film, KBr) 3443 (br), 2941 (w), 2857
(w), 2098 (m), 1628 (s), 1441 (m), 1268 (w), 1223 (w), 1142 (w), 1014 (w) cm-1. 1H NMR (400
MHz, CDCl3) δ 3.76 – 3.62 (t, 2H), 3.62 – 3.48 (t, 2H), 1.73 – 1.59 (m, 4H), 1.59 – 1.49 (m,
2H). 13C NMR (100 MHz, CDCl3) δ 151.7 (s), 73.7 (s), 55.3 (s), 48.3 (s), 42.7 (s), 26.6 (s), 25.5
(s), 24.6 (s). HRMS (ESI+) m/z calc’d for C8H11BrNO+: 216.0019. Found: 216.0025.

3.10.3. Synthesis and characterization of 8-oxabicyclo[3.2.1]octene (3.35a)

3-methoxy-5-methyl-6-(piperidine-1-carbonyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-2-one
(3.35a). To a solution of dimer 3.28b (325 mg, 1.16 mmol) in DCM (4.63 mL)
was added 1-(piperidin-1-yl)prop-2-yn-1-one 3.34a (954.3 mg, 6.96 mmol).
After heating in an oil bath at 100 °C for 90 min, the reaction mixture was
purified by chromatography (Biotage Isolera Prime, 25 g silica gel column
capped with triethylamine, solvent gradient: 2% EtOAc in hexanes (3 CV); 2-10% EtOAc in
hexanes (5 CV); 15-25% EtOAc in hexanes (15 CV); 25-35% EtOAc in hexanes (8 CV); 3560% (8 CV)). Product fractions were concentrated to yield 3.35a as a yellow solid that melts at
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122-124 °C (417.9 mg, 65% yield). Rf= 0.32 in 25% EtOAc in hexanes. IR (thin film, KBr)
2937 (s), 2858 (s), 1708 (s), 1605 (s), 1443 (s), 1375 (w), 1347 (w), 1286 (m), 1179 (m), 1130
(m), 1078 (m), 988 (m), 863 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.26 (d, J = 2.4 Hz, 1H),
6.23 (s, 1H), 5.07 (d, J = 2.4 Hz, 1H), 3.68 – 3.59 (m, 2H), 3.57 (s, 3H), 3.54 – 3.44 (m, 2H),
1.74 – 1.64 (m, 2H), 1.61 (s, 3H), 1.59 – 1.49 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 188.6,
163.6, 150.6, 144.9, 127.5, 121.4, 87.2, 86.7, 54.6, 47.7, 42.6, 26.8, 25.6, 24.5, 20.5. HRMS
(ESI+) m/z calc’d for C15H20NO4+: 278.1387. Found: 278.1390.

3.10.4. Synthesis and Characterization of Troponoids via Triflic Acid

2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one
(3.8). To a solution of 8-oxabicyclo[3.2.1]octane intermediate 3.35a (100.4 mg, 0.362 mmol) in
dried, deacidified DCM (3.60 mL) was added triflic acid (128.1 μL,
1.5 mmol). The reaction was allowed to stir for 35 minutes at rt before
quenching with pH 7 phosphate buffer and extracting with CH2Cl2.
Combined

organics

were

dried

over

Na2SO4,

filtered,

and

concentrated under reduced pressure to yield 3.8 as a pale green/brown solid that melts at 166169 °C (97.3 mg, 97% yield). IR (thin film, KBr) 3447 (br), 2938 (m), 2856 (m), 1735 (w),
1620 (s), 1560 (m), 1446 (m), 1325 (w), 1257 (s), 1136 (w), 1152 (w), 1026 (w), 996 (w). 1H
NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 7.02 (s, 1H), 4.00 (s, 3H), 3.85 – 3.57 (m, 2H), 3.28 –
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3.10 (m, 2H), 2.41 (s, 3H), 1.67 (d, J = 4.7 Hz, 4H), 1.61 – 1.37 (m, 2H). 13C NMR (100 MHz,
CDCl3) δ 170.5, 168.7, 159.6, 158.6, 136.7, 132.9, 121.6, 115.9, 56.5, 47.7, 42.5, 26.4, 25.5,
24.4, 24.3. HRMS (ESI+) m/z calc’d for C15H20NO4+: 278.1387. Found: 278.1380.

3-bromo-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien1-one (3.18). To a solution of dimer 3.28b (45.8 mg, 0.163 mmol) in DCM (577 μL) was added
3-bromo-1-(piperidin-1-yl)prop-2-yn-1-one (3.34b) (312.1 mg, 1.44
mmol). After microwave irradiation at 100 °C for 35 min, the reaction
mixture was purified by chromatography (Biotage Isolera Prime, 10 g
silica gel column, solvent gradient: 5% EtOAc in hexanes (3 CV); 515% EtOAc in hexanes (15 CV); 15-25% EtOAc in hexanes (15 CV); 25-35% EtOAc in hexanes
(8 CV); 35-50% (5 CV)). Product fractions were concentrated to yield 3.35b as a semi-pure
product that was used without further purification. To a solution of 8-oxabicyclo[3.2.1]octane
intermediate 3.35b (10.9 mg, 0.031 mmol) in dried, deacidified DCM (305 μL) was added triflic
acid (10.8 μL, 0.122 mmol). The reaction was allowed to stir for 30 minutes at rt before
quenching with pH 7 phosphate buffer and extracting with CH 2Cl2. Combined organics were
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 3.8 as a pale
yellow/brown waxy solid (6.3 mg, 50% yield over two steps). IR (thin film, KBr) 3424 (br),
2936 (w), 2854 (w), 1632 (w), 1571 (m), 1445 (w), 1352 (m), 1265 (m), 1247 (w), 1169 (w),
1136 (w), 1077 (w), 787 (w). 1H NMR (400 MHz, CDCl3) δ 7.02 (s, 1H), 4.01 (s, 3H), 3.90 –
3.56 (m, 2H), 3.32 – 3.10 (m, 2H), 2.48 (s, 3H), 1.86 – 1.57 (m, 4H), 1.57 – 1.41 (m, 2H).
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C

NMR (100 MHz, CDCl3) δ 167.4, 166.4, 159.1, 157.2, 139.5, 131.3, 121.7, 118.8, 56.9, 47.3,
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42.4, 26.1, 26.0, 25.2, 24.5. HRMS (ESI+) m/z calc’d for C15H19BrNO4+: 356.0492. Found:
356.0502.

3.10.5. Synthesis and Characterization of Troponoids via Electrophilic Aromatic Substitution

3-bromo-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1one (3.18). Procedure A: To a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1carbonyl)cyclohepta-2,4,6-trien-1-one 3.8 (10.8 mg, 0.039 mmol) in
CDCl3 (1.30 mL) was added dibromodimethylhydantoiin (DBDMH)
(14.25 mg, 0.05 mmol), followed by triethylamine (5.4 μL, 0.039
mmol). The reaction was allowed to stir for 2 hours at rt before
quenching with pH 3 phosphate buffer and extracting with CH2Cl2. Combined organics were
dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 3.18 as a pale
yellow/brown waxy solid (5.6 mg, 88% yield) with 1H-NMR data consistent with previously
reported data. See Section 3.10.4 for characterization data.
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Procedure B: N-Bromosuccinimide (NBS, 1.1 equiv.) was added to a 0.02 M solution of
tropamide 3.8 (17.3 mg, 0.062 mmol, 1 equiv) and catalyst 3.38 (3.5
mg, 0.006 mmol, 0.1 equiv) in CDCl3 (3.12 mL) at 0 ºC. The reaction
was allowed to stir for 72 hours. The reaction was then diluted with 4
mL of DCM, transferred to a separatory funnel, and quenched with an
equivalent volume of a pH 3 phosphate buffer (made by diluting 1.7 mL of 2.0 M aqueous
sulfuric acid with 12 mL of 1.0 M pH 7 phosphate buffer), and extracted 3x. The combined
organics were dried over sodium sulfate, filtered, and concentrated under reduced pressure.
Reversed phase chromatography of the crude residue with water/acetonitrile was accomplished
on a Biotage Isolera Prime (SNAP 12g C18 silica gel column, solvent gradient: 10% acetonitrile
in water (3 CV); 10-23% (8 CV), 23-35% (8 CV), 35-100% (6 CV); acetonitrile and water each
contained 0.05% TFA). Product fractions were combined, extracted with excess DCM (3x, Σ =
60 mL), filtered through Na2SO4 and concentrated at 30 °C in vacuo, yielding 3.18 as a waxy
brown/yellow solid (11.2 mg, 50% yield) with 1H-NMR data consistent with previously reported
data. See Section 3.10.4 for characterization data. HPLC 75:25 er (Chiralpak IA, 1.5 mL/min,
35% acetonitrile in water with 0.1% formic acid): RT(minor) = 7.2 min, RT(major) = 8.1 min.
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3.10.6. Synthesis and Chiral Resolution of αHT 3.39

3-bromo-2,7-dihydroxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one

(3.39). Procedure: To methoxytropolone 3.18 (20.3 mg, 0.057 mmol) was added 892 μL of 33%
HBr/AcOH. The reaction was heated in a sealed tube to reflux at 120 °C for
30 minutes before being quenched to pH 4 with pH 7 phosphate buffer. The
organic layer was isolated and the aqueous later was extracted with CH 2Cl2 (5
x 10 mL). Combined organics were dried over Na2SO4, filtered, and
concentrated under reduced pressure to yield 3.39 as a waxy brown solid (14.6 mg, 75%). HPLC
55:45 er (Chiralpak IC, 1.5 mL/min, 35% acetonitrile in water with 0.1% formic acid): R T(Ent-1) =
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11.0 min, RT(Ent-2) = 13.7 min; IR (thin film, KBr) 3420 (br), 2936 (m), 2856 (m), 1633 (s),
1542 (m), 1445 (s), 1270 (w), 1230 (w), 1137 (w), 1067 (s), 810 (w), 735 (w). 1H NMR (200
MHz, CDCl3) δ 7.43 (s, 1H), 3.92 – 3.54 (m, 2H), 3.23 – 3.05 (m, 2H), 2.47 (s, 3H), 1.83 – 1.56
(m, 4H), 1.56 – 1.38 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 167.2, 165.3, 157.0, 156.3, 139.8,
134.9, 123.8, 119.6, 47.2, 42.3, 25.9, 25.7, 25.2, 24.5. HRMS (ESI+) m/z calc’d for C14H17NO4+:
342.0335. Found: 342.0390.

Preparatory Chromatography. 10.0 mg of 3.39 were loaded onto a Chiralflash IC column (100
mm, i.d. 30 mm, particle size 20 μm) fitted with adaptors for use with an MPLC Biotage Isolera
Prime. Conditions: water/acetonitrile/formic acid (70:30:0.1, v/v/v), 12 mL/min, direct load in
water/acetonitrile (30:70, v/v). Fractions containing product for both enantiomers were combined
separately, extracted with excess DCM (3x, Σ = 300 mL), filtered through Na 2SO4 and
concentrated at 30 °C in vacuo, yielding a total of 2.3 mg of 3.39-(Ent-1) and 4.5 mg 3.39-(Ent2). Optical rotation of Ent-1:

+0.114 (c 1.0, CH2Cl2); Ent-2:
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-0.079 (c 1.0, CH2Cl2).

Assessment of chemical purity. Racemic material (red trace, bottom) and isolated enantiomers
(Ent-1 = green trace, middle; Ent-2 = purple trace, top) were compared via UPLC-MS.
Calculated m/z for C14H17NO4+: 342.03. Found: 342.12 (Ent-1); 342.16 (Ent-2).

Assessment of enantiopurity. Each sample was assessed via the reversed phase CSP-HPLC
conditions previously described. 3.39-(Ent-1): >99:1 er. 3.39-(Ent-2): 97:3 er.

Racemic Material:

= 11.0 min,

= 13.7 min.
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3.39-(Ent-1): >99:1 e.r.

3.39-(Ent-2): 3:97 e.r.

3.10.7. Synthesis and Characterization of Thiazolidines

2,7-dihydroxy-4-methyl-5-(thiazolidine-3-carbonyl)cyclohepta-2,4,6-trien-1-one (3.4).
Procedure: To a solution of carboxylic acid 3 3.3 (25.0 mg, 0.127 mmol) in THF (3.18 mL) was
added 2,6-lutidine (33 μL, 0.280 mmol) and benzotriazol-1-yl-oxytripyrrolidinophosphonium
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hexafluorophosphate (PyBOP) (73 mg, 0.140 mmol). The mixture was
allowed to stir for 15 min in the dark at rt under an atmosphere of argon gas.
Thiazolidine (11.1 μL, 0.140 mmol) was then added to the solution. The
reaction was subjected to microwave irradiation at 85 °C for 10 min,
concentrated in vacuo, and dissolved in 800 uL of DMSO for purification via
reverse phase chromatography (Biotage Isolera Prime, SNAP 12g C18 silica gel column, solvent
gradient: 0% acetonitrile in water (3 CV); 0-15% (15 CV); 15-25% (20 CV); 25-50% (8 CV);
50-100% (10 CV); acetonitrile and water each contained 0.05% TFA). Product fractions were
concentrated in vacuo to remove acetonitrile, and the remaining aqueous solution was extracted
with DCM (3 x 15 mL). The combined organics were dried over sodium sulfate, filtered, and
concentrated in vacuo to yield 3.4 as a yellow oil (11.8 mg, 35 % yield). IR (thin film, KBr)
3442 (br), 2075 (w), 1637 (m), 1545 (w), 1488 (w), 1302 (w), 1145 (w), 1056 (w), 1033 (w), 781
(w), 537 (w) cm-1. 1H NMR (400 MHz, MeOD) δ 7.45 (s, 2H), 7.23 (d, J = 2.0 Hz, 2H), 4.71
(ABq, 2H, JAB = 10.3 Hz), 4.29 (ABq, 2H, JAB = 9.5 Hz), 4.02 – 3.84 (m, 2H), 3.63 – 3.43 (m,
2H), 3.23 – 3.12 (m, 2H), 3.11 – 3.00 (m, 2H), 2.36 (d, J = 1.4 Hz, 6H).13C NMR (100 MHz,
DMSO) δ 168.3, 168.3, 167.7, 167.5, 159.3, 159.2, 158.2, 158.2, 135.8, 135.5, 134.7, 134.4,
123.5, 123.4, 117.6, 117.6, 50.1, 49.3, 47.3, 47.0, 30.34, 29.3, 22.9, 22.8. For 2D NMR
experiments, see Section 3.10.10. HRMS (ESI+) m/z calc’d for C12H14NO4S+: 268.0638. Found:
268.0639.

(5-hydroxy-2-methylphenyl)(thiazolidin-3-yl)methanone (3.6).
Procedure: To a solution of carboxylic acid 3.5 (19.3 mg, 0.127 mmol) in THF (3.18 mL) was
added 2,6-lutidine (33 μL, 0.280 mmol) and benzotriazol-1-yl-oxytripyrrolidinophosphonium
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hexafluorophosphate (PyBOP) (73 mg, 0.140 mmol). The mixture was
allowed to stir for 15 min at rt under an atmosphere of argon gas. Thiazolidine
(11.1 μL, 0.140 mmol) was then added to the solution. After microwave
irradiation at 85 °C for 10 min, the reaction mixture was purified by chromatography (Biotage
Isolera Prime, 10 g silica gel column, solvent gradient: 5% EtOAc in hexanes (3 CV); 5-25%
EtOAc in hexanes (12 CV); 25-30% EtOAc in hexanes (5 CV); 30-50% EtOAc in hexanes (10
CV); 50-100% (20 CV)). Product fractions were concentrated to yield 3.6 as a white solid (16.2
mg, 57% yield). Rf= 0.22 in 50% EtOAc in hexanes Melting point (mp) = 139-141 °C. IR (thin
film, KBr) 3423 (br), 1608 (s), 1450 (s), 1336 (w), 1291 (m), 1261 (w), 1236 (m), 1095 (w), 822
(w), 713 (w) cm-1. 1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, CDCl3) ä 7.51 – 7.28 (bs,
2H), 7.01 (dd, J = 8.3, 3.9 Hz, 2H), 6.76 – 6.68 (m, 2H), 6.61 (dd, J = 8.0, 2.3 Hz, 2H), 4.75 (s,
2H), 4.20 (s, 2H), 3.99 (t, J = 6.5 Hz, 2H), 3.49 (t, J = 6.2 Hz, 2H), 3.11 (t, J = 6.5 Hz, 2H), 2.95
(t, J = 6.2 Hz, 2H), 2.19 (d, J = 4.3 Hz, 6H).

C NMR (100 MHz, CDCl3) δ 170.4, 170.2,
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154.7, 136.9, 136.6, 132.0, 131.9, 125.1, 124.7, 117.4, 117.4, 113.0, 112.9, 51.2, 50.4, 47.9, 47.6,
30.9, 30.3, 18.1. For 2D NMR experiments, see Section 3.10.10.. HRMS (ESI+) m/z calc’d for
C11H14NO2S+: 224.0740. Found: 224.0778.

3.10.8. Determination of Kinetic Parameters via Dynamic NMR Studies
Lineshape simulation of the spectra was performed using the iNMR software (Version 6),
which gave a rate constant (k) at a range of temperatures. These were converted into rotational
barriers using the Eyring equation:
Eq. S3.1

This equation can be rearranged into the form:
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Eq. S3.1A

The plot of ln(k/T) vs 1/T gives a straight line fitting the form y=mx+b. The slope (m) gives the
enthalpy of rotation (ΔH‡):
Eq. S3.2
The y-intercept (b) gives the entropy of rotation (ΔS‡):
Eq. S3.3
Inserting these values into Gibbs’ equation for free energy (ΔG ‡ = ΔH‡ – TΔS‡) gives an
estimation of ΔG‡298K. (kB – Boltzmann constant, h – Planck’s constant, R – universal gas
constant, T = 298 K).
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A) Determination of C-C Barriers

For troponoid 3.4, lineshape fitting was performed on peaks AZ, BZ, CZ, AE, and BE. Due
to its complex splitting pattern, accurate simulation of troponoid signal C E proved problematic.
The reported kinetic parameters (Figure S3.1) represent averages of the values obtained for these
signals. Fitting 1H-NMR data at temperatures above 353 K was impractical due the amide
rotamer signals beginning to coalescence. In the case of benzenoid 3.6, lineshape fitting was
performed on AE, BZ, BE, and CE. Simulation of peak CZ proved similarly challenging, and
resolution of peak AZ was not observed. While it was initially suspected that this effect may be
indicative of rotamer Z possessing a higher energy C-C barrier, given that the other Z signals all
coalesce, it can be concluded that the chemical shifts of the Z rotamer’s atropdiastereotopic
protons are coincidentally equivalent.
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Troponoid 3.4: Peak AZ
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

4.5

-4.194

323

0.003095

21

-2.734

333

0.003002

45

-2.002

343

0.002914

89

-1.349

353

0.002832

167.3

-0.747

Table S3.1. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak AZ of troponoid 3.4.

Troponoid 3.4: Peak AE
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

2.37

-4.835

323

0.003095

16.37

-2.982

333

0.003002

35.37

-2.243

343

0.002914

72.64

-1.553

353

0.002832

159.19

-0.797

Table S3.2. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak AE of troponoid 3.4.

Troponoid 3.4: Peak BE
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

5.5

-3.993

323

0.003095

17.5

-2.916

333

0.003002

36.5

-2.211

343

0.002914

66

-1.649

353

0.002832

106.1

-1.202

Table S3.3. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak BE of troponoid 3.4.
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Troponoid 3.4: Peak BZ
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

5

-4.088

323

0.003095

25.5

-2.539

333

0.003002

45

-2.002

343

0.002914

89

-1.350

353

0.002832

152.73

-0.838

Table S3.4. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak BZ of troponoid 3.4.

Troponoid 3.4: Peak CZ
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

5

-4.088

323

0.003095

26

-2.520

333

0.003002

63.5

-1.658

343

0.002914

92

-1.316

353

0.002832

n/a

n/a

Table S3.5. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak CZ of troponoid 3.4.

Benzenoid 3.6: Peak AE
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

213

0.004692

5

-3.752

223

0.004481

19.7

-2.427

233

0.004289

62.7

-1.313

243

0.004113

144.08

-0.523

258

0.003874

421.5

0.490

Table S3.6. Rate constants k for isomerization at given temperatures T, with Eyring plot used to
determine kinetic parameters from peak AE of benzenoid 3.6.
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Benzenoid 3.6: Peak BE
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

213

0.004692

13.5

-2.759

223

0.004481

34

-1.881

233

0.004289

87.5

-0.980

243

0.004113

197.34

-0.209

258

0.003874

476.2

0.612

Table S3.7. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak BE of benzenoid 3.6.

Benzenoid 3.6: Peak BZ
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

213

0.004692

5

-3.752

223

0.004481

19.5

-2.437

233

0.004289

54.5

-1.454

243

0.004113

69

-1.260

258

0.003874

600

0.843

Table S3.8. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak BZ of benzenoid 3.6.

Benzenoid 3.6: Peak CE
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

213

0.004692

12

-2.877

223

0.004481

29

-2.051

233

0.004289

61

-1.341

243

0.004113

162.22

-0.405

258

0.003874

617.14

0.872

Table S3.9. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak CE of benzenoid 3.6.
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B) Determination of Benzenoid C-N Barrier
For benzenoid 3.6, lineshape fitting to determine the C-N amide isomerization barrier was
performed on peaks AE and AZ. Since there is a slightly higher population of the Z rotamer as
visible by 1H-NMR (integration of AE:AZ = 1.0:1.1), separate analyses were carried out for each
isomer (Figure S3.2). As this effect is minor, the reported rotational barrier (see main text)
represents an average of these two values.

Analysis of the ‘A’ peaks gave rate constants k at temperatures spanning 298-373 K
(Tables S3.10-S3.11). Using the method described above, these rate constants were used to
calculate the reported kinetic parameters.
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Benzenoid 3.6: Peak AZ (representing Z  E isomerization)
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

6.50

-3.826

303

0.003299

7.25

-3.733

313

0.003193

18.25

-2.842

323

0.003095

36.75

-2.174

333

0.003002

81.75

-1.405

343

0.002914

157.70

-0.777

353

0.002832

307.54

-0.138

363

0.002754

627.12

0.546

373

0.002680

1027.00

1.012

Table S3.10. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak AZ of benzenoid 3.6.

Benzenoid 3.6: Peak AE (representing E  Z isomerization)
T (K)

1/T (K-1)

k (s-1)

ln(k/T)

298

0.003354

7.50

-3.683

303

0.003299

8.25

-3.604

313

0.003193

23.75

-2.580

323

0.003095

44.25

-1.988

333

0.003002

87.75

-1.334

343

0.002914

169.17

-0.707

353

0.002832

336.57

-0.048

363

0.002754

627.12

0.546

373

0.002680

1027.00

1.012

Table S3.11. Rate constants k for isomerization at given temperatures T, with Eyring plot used to determine kinetic
parameters from peak AE of benzenoid 3.6.
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3.10.9. Experimental Barrier Determination of 3.18 via Thermal Racemization
To an oven-dried 1 dram vial equipped with a stir bar was added a solution (5.6 mM) of
3.18 (5.0 mg, 50% ee) in triethylene glycol dimethyl ether (triglyme, 2 mL). The vial was sealed
with a puncturable septa-lined cap and heated in an oil bath (equipped with a temperature probe
and a thermometer to confirm temperature) at 145 °C. The enantiomeric ratio was measured by
reversed phase CSP-HPLC (I-A column, 35% acetonitrile in water with 0.1% formic acid
additive, 5 uL injection volume, 1.5 mL/min; monitored at 265 nm) at time points spanning 1 to
90 minutes. Aliquots of 60 μL were withdrawn from the reaction vessel and quickly diluted in 40
μL of stock 3:1 ACN:H2O solution at 0 °C before analysis (see Figure S3.4 for a representative
example). Plots of ee versus time, and of ln(1/ee) versus time were generated from the data
described in Tables S3.12-S3.14, and resulted in the respective graphs shown below (Figure
S3.4).

Figure S3.3. Representative example (trial 1) of HPLC traces monitoring thermal racemization of 3.18 at 418K in
triglyme.
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Table S3.12. Enantiomeric excess measured at various timepoints with HPLC spectra, trial 1.

Trial 1
Entry

1

2

3

4

5

6

Time (s)

69.00

185.00

310.00

725.00

1507.00

3613.00

ee (x 10-2, %)

0.494

0.356

0.188

0.118

0.112

0.092

ln(1/ee)

0.705

1.03

1.67

2.14

2.19

2.39

Table S3.13. Enantiomeric excess measured at various timepoints with HPLC spectra, trial 2.

Trial 2
Entry

1

2

3

4

5

6

7

Time

123.00

247.00

361.00

479.00

602.00

1204.00

5393.00

ee (x 10-2, %)

0.432

0.246

0.178

0.148

0.118

0.118

0.114

ln(1/ee)

0.840

1.40

1.73

1.91

2.14

2.14

2.17

Table S3.14. Enantiomeric excess measured at various timepoints with HPLC spectra, trial 3.

Trial 3
Entry

1

2

3

4

5

6

7

8

Time

90.00

166.00

234.00

300.00

363.00

425.00

505.00

604.00

ee (x 10-2, %)

0.458

0.336

0.226

0.176

0.154

0.120

0.116

0.110

ln(1/ee)

0.781

1.09

1.49

1.73

1.87

2.12

2.15

2.21
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Figure S3.4. Plots measuring enantiomeric excess vs time.

Racemization rate constants (krac) were derived from the slopes of the lines shown in
Figure S3.4. The rate constants to enantiomerization, kenant, were obtained by halving krac values.
Using a rearranged form (Eq. S3.1B) of the Eyring equation described above (Eq. S3.1), the free
activation energies of racemization (ΔG‡rac) and enantiomerization (ΔG‡enant) were determined.
These values are summarized in Table S3.15.
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Eq. S3.1B

Table S3.15. Experimentally determined rate constants and rotational barriers of 3.18 at 145 °C.
Trial

krac (s-1)

1

0.00402

ΔG‡ rac
(kcal/mol)
29.372

0.00201

ΔG‡enant.
(kcal/mol)
29.948

2

0.00300

29.615

0.00150

30.192

3

0.00400

29.377

0.00200

29.954

kenant. (s-1)

155

Average
ΔG‡enant.
30.03
kcal/mol

3.10.10. NMR Spectra of New Compounds
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Chapter IV
Atropselective Halogenation of Troponoids
4.1. Introduction
Atropisomerism, a form of chirality arising from restricted rotation about a chiral axis,
plays an important role in a number of scientific pursuits including ligand development (e.g. 4.1,1
Figure 4.1),2 molecular devices, 3 and drug discovery.4 While such rotationally restricted scaffolds
are ubiquitous among modern therapeutics, single-atropisomer drugs are rarely created by design,
and are instead frequently based on natural products (e.g. 4.25 and 4.3,6 Figure 4.1).7 Given the
critical importance of chirality in drug development,8 and the potential target selectivity increases
of single-atropisomer drugs, they are also becoming increasingly prevalent in de novo drug design
(4.4,9 Figure 4.1).10 As was discussed in Chapter 3, this paradigm shift has the potential to usher
in a new wave of atropisomerically pure drugs that have enhanced selectivity profiles over
analogous racemic or racemizable compounds. Synthetic efforts towards selective formation of
single-atropisomer bioactive molecules therefore constitute an essential area of study that is
rapidly garnering increasing attention from medicinal, synthetic, and physical chemists alike
(Scheme 4.1).
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Approaches involving applications of various chiral reagents are described in the literature.
One classic example of this strategy is the work of Bringmann, who was able to perform an
asymmetric CBS reduction of lactone 4.5 using a chiral reducing agent (S)-oxazaborolidine 4.6 to
access 4.7 (a precursor to natural product dioncopeltine A) with excellent selectivity (Figure
4.2A).11 Chiral auxiliaries have also found utility in this regard. In 2012, Colobert and coworkers
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reported a highly atropselective synthesis of the biaryl moiety (4.10) of vancomycin using a
ß-hydroxysulfoxide auxiliary (Scheme 4.1B).12 More widely studied, however, are techniques for
atropselective cross-coupling, which by nature are more efficient transformations since no
attachment/removal of an auxiliary is required. The first reported example of an atropselective
cross-coupling was published by Makoto Kumada in 1975 (Scheme 4.1C).13 Using ligands 4.14
and 4.15 he was able to access binapthyl compound 4.13 via a chiral phosphine-nickel catalyst.
While this transformation was achieved with modest selectivity, it represents a breakthrough in
atropselective synthesis and has set the stage for numerous advancements in this field. One such
example comes from the laboratory of Buchwald and coworkers, who reported efficient syntheses
of axially chiral biaryl amides (such as 4.18, Scheme 4.1D). These were reported in high yields
and enantioselectivities via an asymmetric Suzuki coupling with KenPhos 4.19 as a ligand.14
Despite these advancements, atropselective synthetic methods are often stifled by the
exceptionally high rotational barriers (>28 kcal/mol) needed to maintain configurational stability. 15
This is especially problematic in the development of atropselective transformations for biological
studies, where physiological conditions and metabolic processes can further influence these
barriers.16 The following chapter describes a solution to these challenges by outlining a new
synthetic strategy to access enantioenriched troponoids. Troponoids are bioactive non-benzenoid
aromatic molecules that are predicted to have remarkably high barriers compared to the 5- and 6membered rings commonly found in drugs (see Chapter 3 for more details). This is due to their
decreased external bond angles and increased sensitivity to the so-called “buttressing effect”
(Figure 4.2A).17 However, other features such as tropylium characteristics, 18 ring puckering,19
and decreased aromaticity20 could influence the rotational barriers as well. To the best of our
knowledge, the only troponoid known to be atropisomeric is colchicine (4.3, Figure 4.1A, ΔG‡ =
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22 kcal/mol) and related analogs. Interestingly, while it would be expected to racemize within
minutes at room temperature, an added stereocenter renders the aS form more thermodynamically
favorable.6 The only other troponoid known to possess any degree of atropisomerism is bistropone
homodimer 4.20, which has a relatively low barrier to isomerization (ΔG‡ = 20.7 kcal/mol) such
that it can only undergo chiral resolution at decreased temperatures (Figure 4.2B).21 Given the
growing interest in troponoid drug development by our group22 and others,23 as well as the
importance of atropisomerism throughout the field of chemistry, the development of an
asymmetric, catalytic method of single-atropisomer troponoid synthesis would significantly
advance biological studies on these molecules. To date, no such methods exist.

To address this limitation, we turned our attention to atropselective halogenation. This
technique has recently emerged as a viable synthetic strategy towards accessing enantioenriched
benzamides,24 biaryls, 25 quinazolinones, 26 quinolines, 27 and other scaffolds (Scheme 4.2A).28
These transformations are typically dynamic, kinetic resolutions that are mediated by bifunctional
organocatalysts capable of recognizing specific substrate conformations through hydrogenbonding interactions.29 However, these methods have found limited application in the synthesis of
single-atropisomer drugs and drug candidates. 30 We therefore began our studies by investigating
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atropselective troponoid synthesis via a peptide-catalyzed halogenation strategy developed by
Scott Miller’s group at Yale University. 24-26 This approach exploits differences in rotational
barriers around a chiral axis before and after bromination and has been applied to a range of
scaffolds including benzamides (i.e. 4.25  4.26, Scheme 4.2B),24 which are close troponoid
homologs. Prior studies indicate that effective catalysis is contingent on certain structural features
of the peptide (e.g. 4.29l),26 primarily revolving around functional groups capable of forming
H-bond contacts between the catalyst and the substrate.31 These include the basic
β-dimethylaminoalanine (Dmaa) residue (which is capable of targeting acidic moieties on the
substrate) as well as the capacity to exist in a β-hairpin structure (Scheme 4.2B).32
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More recent 1H-NMR and DFT studies further support this hypothesis.33 Furthermore,
selectivity is likely provided by substrate H-bond donor and acceptor groups flanking the
bromination site (see Chapter 3 for details). As these features are shared by our synthetic
troponoid scaffolds, we became intrigued by the possibility of using these peptides to halogenate
troponoids (i.e. 4.27  4.28), and thus initiated a collaboration with the Miller group to develop
the first ever method for atropselective troponoid synthesis.

4.2. Catalyst Identification
Our studies began with a screen of peptide-based catalysts for the bromination of
amidotroponoid 4.27 using the conditions described in Scheme 4.3. Our choice of catalysts was
guided by previous reports from the Miller group on analogous scaffolds,24,26 wherein the Dmaa
residue was embedded into a sequence that was capable of adopting a β-turn geometry (i.e.,
H-bonding between the i and i+3 residues, Scheme 4.2, shown in red).32,34 These characteristics
were predicted to facilitate selective complexation with one atropisomer of (±)-4.27 over the other.

In the absence of catalyst, bromination of 4.27 was nonselective and sluggish (Scheme 4.3). In
the presence of triethylamine as a catalyst, however, the reaction provided 50% conversion of racemic
4.28. Site-selectivity was confirmed by synthesis of the authentic isomer via the regioselective
oxidopyrylium cycloaddition/ring-opening strategy discussed in Chapter 3. Upon observing identical
1

H-NMR profiles, we began to assess peptide-based catalysts for this transformation at a variety of

temperatures. Where possible, the reactions were monitored by 1H-NMR and run to full conversion.
The results of this optimization are summarized in Table 4.1 below.
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Gratifyingly, peptides 4.29a, 4.29i, 4.29l, 4.29o, and 4.29q (highlighted in blue in Table
4.1) were discovered to promote conversion to bromotroponoid 4.28 in roughly 40-50% ee.
Consistent with previous reports, these catalysts are known to be capable of adopting β-turn
geometries that have been demonstrated to be necessary for enantioselectivity in related
scaffolds.33,35 Effective catalysts were found to share several other structural characteristics,
including a Dmaa residue at the i position. A preliminary investigation into the impact of the i
residue provided some insights into the mechanism of bromination (Figure 4.3). It was found that
increasing the pKa of this functionality (as in the case of the tetramethyl guanidine (Tmga), Entry
12) resulted in a nonselective reaction. Similarly, π-methyl histidine- and threonine-based catalysts
4.29z and 4.29aa (Entries 27 and 28, respectively) also resulted in racemic reactions. New
synthetic constructs with aryl rings at the i position (4.29t, 4.29u, 4.29v; Entries 21-23) were
synthesized in hopes of engaging in favorable π/π stacking interactions between the catalyst and
substrate. This proved not to be the case. The nature of substrate/catalyst complexation is
contingent on many factors, and is the result of multiple dynamic processes and interactions. The
change in both steric and electronic factors may both be responsible for these peptides adopting an
unfavorable geometry.

The efficacy of peptide-catalyzed reactions is often particularly sensitive to functionality
at the i+2 position.26 This position plays a key role in determining certain structural attributes of
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the peptide.33 Upon examining this residue, we observed pronounced differences in selectivity
resulting from seemingly minor alterations (as in 4.29a, 4.29b, 4.29c; see Figure 4.4). Indeed, in
prior desymmetrization bromination studies, enantiodivergent catalysis has been observed using
similar catalysts, featuring either a cyclopropyl or an aminoisobutyramide residue which differ by
only 2 amu.36 While this effect is not fully understood, a linear correlation has previously been
observed between enantioselectivity and the τ(i+2) angle in the bromination of axially chiral
quinazolinones. This angle is a function of the dihedral ϕ and ψ angles of the i+2 position and
impacts the nature of the β-turn geometry.33 Accordingly, a difference of 36% ee was observed
(Entries 2 and 3). Additionally, a similar effect was observed when comparing cycloheptyl- and
cyclooctyl-substituted catalysts 4.29n and 4.29o (Entries 15 and 16), wherein selectivity was
doubled with addition of a single methylene unit in a substituent with existing steric bulk.

Having identified the Boc-Dmaa-DPro-Aib sequence to be optimal, we began to assess i+3
substituents. In so doing, we again observed a high degree of sensitivity of catalytic activity
towards seemingly subtle structural changes to the peptide scaffold. In addition to changes in
peptidic secondary structural attributes, a more obvious steric element may also be in effect. While
the degree of enhancement observed across the span of several i+2 residues (Acpc, Acbc, Aib) is
likely too large to be explained by sterics alone, an interesting trend was observed between valine,
isoleucine, and tert-leucine-substituted peptides. While valine at the i+3 position was found to
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deliver bromotroponoid 4.28 in up to 50% ee, isoleucine substitution decreased catalytic activity
by nearly half (32% ee, Entry 19), and tert-butyl leucine was nonselective (Entry 20; see Figure
4.5). This trend is reflected in the reported A-values of isopropyl and tert-butyl substituents,
potentially suggesting a steric component to achieving favorable substrate-catalyst interactions.37
Moreover, a preliminary screen of various C-terminal functionality did not yield any improvement
over peptide leads 4.29a, 4.29i, 4.29l, 4.29o, or 4.29q, highlighting the methyl ester endcap as a
suitable protecting group and thus setting the stage for further reaction optimization.

4.3. Optimization of the Reaction Conditions
Having identified catalysts 4.29a/4.29l and 4.29q as capable of delivering 4.28 in 40% and
50% ee respectively, we looked more closely at probing reaction conditions. These results are
summarized in Table 4.2. Of note, while it was discovered that catalyst 4.29q was capable of
delivering comparable selectivity at 5 mol% as compared to 10 mol% (Entries 28 and 27, Table
4.2), the majority of these studies were performed using 10% catalyst loading. Interestingly, it was
found that stoichiometric peptide proved deleterious to the reaction (Entry 23), and that more dilute
concentrations – while not substantially affecting selectivity – proved detrimental to the isolated
yield (Entry 31).
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We next turned our attention to a screen of bromination reagents. Previous reports from
the Miller lab demonstrate profound selectivity differences depending on the bromonium source. 2426

We thus compared bromination reagents N-bromophthalimide (NBP), N-bromoacetamide

(NBA), and N-bromosaccharin (NBSac) to NBS. Brominating reagent NBS was found to
outperform the others in terms of conversion, yield, and selectivity (Entries 8, 10, 12 and 13).
However, NBP demonstrated comparable selectivity. We hypothesize that this might be an effect
of the dibrominated amide byproduct (Figure 4.6). Whereas succinimide and phthalimide have
similar pKas (9.638a and 8.3,38b respectively), acetamide (pKa = 17)39 and saccharin (pKa = 1.6) 40
are well outside of this range, which may facilitate non-selective peptide/substrate contacts, or
alter their protonation states altogether. Notably, chlorination reagents were also briefly assessed
(Entries 14 and 15) and found to deliver substantially lowered selectivities and decomposition of
substrate to an unidentifiable reaction mixture. However, further investigation of chlorination is
warranted.

Temperature effects were also examined. While colder conditions proved beneficial, NBS
dissolution was poor at temperatures below 0 °C. A similar issue was encountered while
investigating solvent effects, where both NBS and substrate solubility were significantly impacted
by decreases in temperature. Ultimately, CDCl3 proved to be the most effective solvent.
Interestingly, impacts on conversion were observed when CHCl3 was used in place of CDCl3 (not
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shown). Side reactions, potentially with chloroform additive amylene were observed, although the
specific nature of these decomposition pathways is unclear at present.
Deuterated solvents served an additional purpose in allowing us to monitor the progress of
these reactions by 1H-NMR. As such, the reactions were quenched when they reached full
conversion, or when conversion appeared to plateau. Such quenches ranged from basic (Entries
2-4) to acidic in nature. DMAP/Ac2O quenches were employed prior to procurement of reversed
phase chiral HPLC supports, as a means of acetylating 4.28 for ease of normal phase purification.
Head-to-head assessments (not shown) of this quench and an acid quench proved comparable in
terms of selectivity. Acidic quenches were conducted by adding acidic solutions to a pre-made 1.0
M pH 7 phosphate buffer, to reach an ultimate pH of 3. Curiously, the nature of this quench in
certain instances lead to different outcomes in terms of selectivity (vide infra), prompting further
mechanistic investigations.

4.4. Mechanism-Driven Experiments
Examination of certain elements of the reaction optimization inspired us to investigate
mechanistic aspects of this reaction. This was largely borne out of the discovery of
tentatively-assigned intermediate 4.34 upon monitoring the reactions by

1

H-NMR. The

intermediate appears to be related to the mechanism of bromination (see Scheme 4.4) and is
characterized by long-range W-coupling between HC and the proximal methyl group. Further
13

C-NMR and HSQC studies, though not definitive, support this structural hypothesis (see

Supporting Information). The intermediate was observed in all reactions that demonstrated
selectivity, and was absent from the nonselective runs. It was also observed, fleetingly and at trace

189

levels, in a 1H-NMR study of background, uncatalyzed bromination (see Supporting Information
for details).

In cases where intermediate 4.34 was observed, its formation was rapid (immediate), while
rearomatization to product was a slower process (in some cases taking up to a day to convert fully;
see Scheme 4.4). This is particularly perplexing given the increased electrophilicity of troponoids
with respect to benzenoids. In all cases in which this intermediate was observed, consumption of
NBS was observed almost instantly, while formation of brominated product was observed over
significantly longer timeframes (3 hours – 6 days; see Tables 4.1 and 4.2), thus indicating that
NBS is not the direct brominating reagent in this reaction. Overall, these initial observations
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suggest that the sluggishness of the electrophilic troponoids have allowed us to observe phenomena
that would be challenging to observe on a more reactive benzenoid.

4.4.1. Characterization Attempts
Characterization of this intermediate is complicated by its low stability and resulting high
reactivity. These traits coupled with the fact that it exists only fleetingly when in the absence of
catalyst render definitive characterization a challenge. Attempts to isolate it via recrystallization
were unsuccessful, and the molecule predictably proved unstable to a variety of chromatography
conditions.
13

C and HSQC NMR experiments, though not definitive, support the proposed structure of

4.34. Of particular note, the 13C-NMR spectra of 4.34 in comparison to that of 4.28 shows three
new signals characteristic of carbonyls (see Supporting Information). DEPT experiments are also
under investigation to specifically study the nature of the putative sp3 carbon. Stoichiometrically,
it makes sense that this sp3 carbon would be bonded to one proton and one bromine, and while
proton He remains difficult to see by 1H-NMR, there is potential evidence of its existence in the
HSQC spectra (see Supporting Information for details). However, treatment of bromotroponoid
4.28 to excess NBS and 20 mol% peptide 4.29a was found to lead to immediate formation of the
intermediate by 1H-NMR. Identical conditions with succinimide in place of NBS lead to no
reaction (Scheme 4.5). While it is possible that 4.34 and a gem-dibromo variant of 4.34 (as in
4.34a) could coincidentally have identical

1

H-NMR profiles, this remains unlikely.

Stoichiometrically speaking, exclusive formation of gem-dibromo variant 4.34a directly from 4.27
with only 1.1 equivalents of NBS (such as described in Scheme 4.3) would be impossible.
Attempts to definitively characterize this intermediate remain underway.
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4.4.2. Quench Studies
Upon further examination, it was found that in the presence of base, intermediate 4.34 is
immediately quenched. However, quenching of the intermediate did not always lead to formation
of bromotropolone product (Scheme 4.6). Upon allowing the reaction to run to full conversion of
starting material – while in the presence of intermediate – it was observed that addition of base
could lead to reversion back to starting material. This may potentially be explained by an
interaction between intermediate 4.34 and product 4.28. However, both the choice of base and the
reaction time preceding base addition appear to impact the degree to which the reversion occurs.
For instance, in a head-to-head comparison, triethylamine was found to effect a higher degree of
reversion than DMAP. As well, when peptide/substrate/NBS were allowed only 10 minutes to
react prior to base addition, no base-catalyzed reversion to starting material was observed. While
the origin of this effect remains unclear, it appears that the presence of bromotropolone 4.28 is
necessary for reversion to starting material. It also remains a possibility that an early base quench
may take place while some NBS is still present in the reaction. This residual NBS may serve to
buffer adventitious water, which suggests that water may play a role in this reversion mechanism.
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An additional quench that was investigated was previously-reported methyl ketonecontaining troponoid 4.35b (Scheme 4.7). As the brominated variant of this molecule had been
synthesized and characterized,41 any bromination of this compound could be reliably detected.
Therefore, 4.27 was pushed to full conversion to 4.34 (with total consumption of NBS) before
treatment with one equivalent of methyl ketone 4.35b (hypothesized to be capable of existing as
4.35a in the presence of succinimide). While sluggish, bromination of 4.35b was observed to begin
within 55 min, although no reversion of either tropolone to starting material was observed.
Remarkably, this quench also appeared to lead to full racemization of bromotropolone 4.28,
potentially through a racemization equilibrium as outlined in Scheme 4.7. While concrete
conclusions cannot necessarily be drawn from these experiments, it is clear that intermediate 4.34
is serving as a brominating reagent and is potentially responsible for the stunted selectivities
observed in Tables 4.1 and 4.2.
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4.4.3. Halogen Exchange
Given the inconsistency of the base quenches, we elected to reinvestigate acidic quenches
instead. Remarkably, crude material showing no evidence of chlorotropolone 4.36 by 1H-NMR,
upon treatment with an HCl-containing buffer, underwent conversion (to varying degrees) to
aforementioned chlorotropolone 4.36 (Table 4.3).
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Table 4.3. Halogenation exchange upon aqueous workup.

Halogen exchange studies revealed that this conversion did not take place via direct
substitution on the intermediate. While a linear relationship between intermediate and
chlorotropolone may be inferred from Entry 1 (Table 4.3), closer examination reveals that this is
not the case. Instead, it was observed that increasing amounts of intermediate lead to increasing
chlorination in an exponential trend (Figure 4.7). For example, when a nearly 1:1
product:intermediate (4.28 : 4.34) ratio is observed pre-quench, a 6:1 chloro:bromotropolone ratio
is observed post-quench (Entry 2). A similar effect is observed in Entry 3. Plotting of these ratios
gave a second order polynomial fit (R2 = 0.9999), while a plot of the log gave a straight line with
a very high degree of linearity (R2 = 0.9993). While the mechanistic underpinnings behind these
observations at present remain unclear, further investigation may uncover the relationship between
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intermediate 4.34 and the enantioselectivity of the peptide-catalyzed reaction. Interestingly, the
enantioinduction of chlorotropolone 4.36 was found to be comparable to the most selective
bromination reaction (52% ee, Table 4.3), though its presence creates purification challenges
given the similar polarities of 4.28 and 4.36. Ultimately, it was discovered that changing the acid
additive to H2SO4, as well as increasing the reaction time such that all intermediate had reacted,
bypassed this issue.
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4.5. Mechanistic Hypotheses
At the outset of these studies, we hypothesized that reaction of troponoid substrate with the
catalyst would proceed via a transition state analogous to a previously reported atropselective
halogenation (Figure 4.8).24,26 In such systems, 1H-NMR spectra of a 1:1 substrate/peptide
complex shows evidence of such complexation in the form of chemical shift differences between
the complex and both individual molecules. When such titration experiments were carried out on
troponoid 4.27 with catalysts 4.29a, 4.29e, 4.29f and 4.29g, no significant chemical shifts were
observed. While in and of itself not confirmation of the presence or absence of this binding mode,42
it is perhaps indicative of a weaker binding interaction. This seems all the more likely when an
equilibrium as described in Scheme 4.7 is invoked. Bromination at the substrate amide carbonyl
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would block one of the necessary points of contact between substrate and catalyst in this binding
model. Additionally, it remains a strong possibility that succinimide (pKa 9.6)38 deprotonates the
troponoid (pKa ~6-7),43 rendering it incapable of coordinating with the peptide for this second
binding interaction. In spite of this hypothesis, NBS emerged as the lead brominating reagent in
the optimization. However, due to commercial availability, pKas of the amide byproducts were
only studied within certain pKa ranges and thus interference with the proposed binding model
(Figure 4.8C) remains possible.

Thus, the impacts of acid additives were preliminarily assessed. Choice of additive was
guided by three necessary characteristics, namely: low reactivity towards bromination, low
nucleophilicity, and a pKa44 high enough to avoid protonating the catalytic tertiary amine of the
peptide. To this end, nitrophenols 4.40 and 4.41 (Tables 4.4A and 4.4B) were investigated.
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Unfortunately, these were found to have the opposite effect of what was anticipated, and
in fact in the case of 4.40 the selectivity of the reaction was almost completely destroyed (Entry 3
vs Entry 4). Unforeseen complexation of these additives with catalyst, direct protonation of the
catalyst, or π/π and/or π-cation interactions with the substrate may all be responsible for these
effects.
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These aggregate mechanistic observations lead us to the hypotheses outlined in Figure 4.9
In such a mechanistic model, nonlinear conversion of intermediate to chlorotropolone is explained,
since intermediate formation is predicted to feed into formation of a chlorinated variant. The
necessity of the presence of bromotropolone 4.28 alongside intermediate 4.34 for reversion to
starting material in the presence of base may also be rationalized. Additionally, the stunted
enantioselectivity of the reaction may be explained; if brominated product is indeed reacting with
some version of this intermediate, lowered enantioinduction would be expected. Furthermore, if
intermediate 4.34 is serving as a bromination reagent, it may simply be an ineffective one for
atropselective halogenation.
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4.6. Impeding Formation of Intermediate 4.34
Driven by the hypothesis that intermediate 4.34 is somehow contributing to enantioerosion,
we sought to impede its formation. We speculated we might be able to accomplish this and thus
boost enantioselectivity by changing the mode of NBS delivery. Under previous conditions, NBS
was added in one portion at the beginning of the reaction. Therefore, we investigated a slow
addition mode of delivery, where 1.1 equivalents of NBS were added over a 2.5-hour time period.
Unfortunately, this did not prove effective in increasing enantioselectivity (Entries 1 and 2, Table
4.5).

We next sought to examine the effects of running the reaction under NBS-controlled low
conversion, such that formation of an intermediate of the proposed structure 4.34 would be
inhibited. Gratifyingly, a correlation with enantioselectivity was observed (Table 4.5). Under
conditions where 1.1 equivalents of NBS provided 40% ee, it was discovered that 0.5 equivalents
of NBS boosted the selectivity to 48%, a profound improvement. Further cutting the NBS down
to 0.28 equivalents produced an additional enhancement to 52%, which remains one of our highest
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ee’s thus far. These results shed light on the otherwise unclear nature of this reaction. While the
resulting stifled conversions render reagent-controlled low conversion an impractical tactic for
single-atropisomer troponoid synthesis, these results indicate that intermediate suppression is
likely the path forward in optimizing this reaction.

4.7. Conclusions
Herein, the first reported efforts at development of an atropselective synthesis of an axially
chiral troponoid are described. Asymmetric peptide-based catalysis was investigated and found to
be capable of delivering a bromotroponoid in high levels of enantioinduction at 75:25 er. During
the course of these studies, mechanistic discoveries unveiled the existence of a non-aromatic
intermediate that may be simultaneously indicative of atropselectivity while also stimulating
enantioerosion. This bromine-containing intermediate was also found to facilitate delivery of a
chlorotroponoid with substantially higher selectivity than was able to be provided by running the
reaction with a chlorinating agent. While we have made several significant discoveries in the study
of this novel reaction, there remains much to be uncovered, and work is currently ongoing to
ascertain more information on the nature of this intermediate. The highly unstable nature of the
intermediate renders definitive characterization difficult, and speaks to the challenges associated
with optimizing this reaction. Further mechanism-driven experiments may assist in the path
forward.
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4.9. Supplementary Experimental Details
With the exception of those described in the sections below, all peptide catalysts were
synthesized and provided by the Miller laboratory, and characterized by the Miller laboratory as
previously published.S1 HPLC access and assistance was also provided by the Miller laboratory.

4.9.1. General Information.
All starting materials and reagents were purchased from commercially available sources
and used without further purification, with the exception of CH2Cl2, which was purified on a
solvent purification system prior to the reaction. All reactions were performed in oven- or flamedried

glassware.

Commercially

available

dibromodimethylhydantoin

(DBDMH),

N-

bromosuccinimide (NBS), and N-chlorosuccinimide (NCS) were purified by recrystallization from
hot water.
1

H-NMR spectra were obtained on a Bruker 400 MHz spectrometer. 2D NMR spectra were

recorded on Agilent 400, 500, or 600 MHz spectrometers. Chemical shifts are measured using the
solvent residual peak as the internal standard (CHCl3 δ 7.26, MeOH δ 3.31, CH2Cl2 δ 5.32, DMSO
δ 2.50), and reported as follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d =
doublet, t = triplet, dd = doublet of doublet, q = quartet, m = multiplet, dd = doublet of doublets,
ddd = doublet of doublet of doublets, dt = doublet of triplets, dq = doublet of quartet, ABq = AB
quartet), coupling constant (Hz), and integration. 13C NMR shifts are measured using the solvent
residual peak as the internal standard (CHCl3 δ 7.2, MeOH δ 49.0, DMSO δ 39.5), and reported as
chemical shifts.
Infrared (IR) spectral bands are characterized as broad (br), strong (s), medium (m), and
weak (w). Microwave reactions were performed via the Biotage Initiator 2.5. Analytical thin-layer
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chromatography (TLC) was performed using Silica Gel 60 Å F254 pre-coated plates (0.25 mm
thickness). TLC Rf values are reported, with visualization accomplished by irradiation with a UV
lamp or appropriate TLC stain. Purification via normal phase column chromatography was
performed on the Biotage Isolera Prime, with Biotage SNAP 10g or 25g cartridges, in a solvent
system of ethyl acetate and hexanes. Reversed phase chromatography was performed on the
Biotage Isolera Prime with Biotage SNAP C18 12 g cartridges, in a solvent system of water and
acetonitrile with a 0.05% trifluoroacetic acid additive. Column gradients are measured in terms of
column volumes (CV). Mass spectra were recorded on a spectrometer by the electrospray
ionization (ESI) technique with a time-of-flight (TOF) mass analyzer. HPLC analysis was
conducted with an Agilent 1100 series instrument equipped with a diode array detector (λ = 265
nm) and columns (chiral supports) from Daicel Chemical Industries (Chiralpak AS-H for normal
phase, and Chiralpak IA and Chiralpak IC for reversed phase purification) at ambient temperature
unless otherwise noted.

4.9.2. Solution Phase Peptide Synthesis and Characterization
The majority of peptides used in these studies were synthesized and characterized as
reported by the Miller laboratory.S1 Peptides 4.29t-v, however, were synthesized for this work.
This was accomplished using the Boc protecting group strategy2 outlined in aforementioned prior
publications.S1 All amino acid residues and coupling reagents were purchased from commercial
sources.
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Representative Synthesis and Characterization of Peptide Catalyst 4.29u

Boc-Phe-DPro-Aib-Phe-OMe (4.29u).
Peptide S4.3 was synthesized as reported previously.S1 To a flask containing trimer S4.3 (84 mg,
0.21 mmol), HOBt H2O (38 mg, 0.28 mmol, 1.3 eq) and a stir bar was added
N-Boc-L-phenylalanine (Boc-Phe-OH; 68 mg, 0.25 mmol, 1.2 eq). The solid
mixture was dissolved in dry CH2Cl2 (1.05 mL, 0.20 M with respect to S4.3).
EDC HCl (54 mg, 0.28 mmol, 1.3 eq) was then added. The resulting solution
was left to stir at RT as DIPEA (97 μL, 0.55 mmol, 2.6 eq with respect to S4.3) was slowly added.
The solution was allowed to stir for 18 hours before being diluted with 20 mL CH2Cl2, poured into
a separatory funnel, and washed with an equivalent volume of 10% aqueous (w/v) citric acid. The
organic layer was separated and subsequently washed with an equivalent volume each of saturated
aqueous NaHCO3 and brine. Organic layers were combined, dried over anhydrous sodium sulfate,
filtered, and concentrated under reduced pressure to provide 4.29u as a white solid (105 mg, 74%
yield). Rf = 0.76 in 10% MeOH in CH2Cl2. IR (thin film, KBr) 3323 (br), 2978 (w), 2360 (m),
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2341 (m), 1745 (w), 1637 (w), 1454 (m), 1366 (m), 1270 (w), 1245 (m), 1170 (s), 701 (w), 669
(w) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 4H), 7.26 – 7.17 (m, 6H), 7.14 (d, J =
7.6 Hz, 1H), 6.77 (s, 1H), 5.52 (d, J = 7.1 Hz, 1H), 4.82 (dd, J = 14.1, 7.5 Hz, 1H), 4.55 (q, J = 7.5
Hz, 1H), 4.18 (dd, J = 8.0, 3.6 Hz, 1H), 3.66 (s, 3H), 3.61 – 3.53 (m, 1H), 3.13 (ddd, J = 21.2, 13.8,
6.8 Hz, 3H), 3.01 – 2.99 (bs, 1H), 2.99 – 2.96 (bs, 1H), 2.80 (dt, J = 9.6, 7.5 Hz, 1H), 2.13 – 2.04
(m, 1H), 1.93 – 1.82 (m, 1H), 1.71 – 1.63 (m, 1H), 1.61 – 1.50 (m, 1H), 1.45 (s, 3H), 1.40 (s, 9H),
1.34 (s, 3H).

13

C NMR (100 MHz, CDCl3) δ 173.8, 172.4, 171.7, 170.5, 136.6, 136.4, 129.4,

129.4, 128.5, 128.4, 127.1, 126.8, 79.9, 60.9, 57.2, 54.0, 53.3, 52.1, 47.2, 39.1, 38.0, 28.4, 27.9,
25.9, 24.9, 24.6 HRMS (ESI+) m/z calculated for C33H45N4O7+: 609.3283. Found: 609.3221.

Boc-[Phe-F5]-DPro-Aib-Phe-OMe (4.29t).
Peptide S4.3 was synthesized as reported previously.S1 To a flask containing trimer S4.3 (84 mg,
0.21 mmol), HOBt H2O (38 mg, 0.28 mmol, 1.3 eq) and a stir bar was added
N-Boc-L-pentafluorophenylalanine (Boc-[Phe-F5]-OH; 89 mg, 0.25 mmol,
1.2 eq). The solid mixture was dissolved in dry CH2Cl2 (1.05 mL, 0.20 M
with respect to S4.3). EDC HCl (54 mg, 0.28 mmol, 1.3 eq) was then added.
The resulting solution was left to stir at RT as DIPEA (97 μL, 0.55 mmol, 2.6 eq with respect to
S4.3) was slowly added. The solution was allowed to stir for 12 hours before being diluted with
20 mL CH2Cl2, poured into a separatory funnel, and washed with an equivalent volume of 10%
aqueous (w/v) citric acid. The organic layer was separated and subsequently washed with an
equivalent volume each of saturated aqueous NaHCO3 and brine. Organic layers were combined,
dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Reversed
phase chromatography of the crude residue with water/methanol was accomplished on a Biotage
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Isolera Prime (SNAP 12g C18 silica gel column, solvent gradient: 10% methanol in water (3 CV);
10-30% (4 CV), 30-100% (16 CV); methanol and water each contained 0.05% TFA; monitored at
210 nm and 254 nm). Product fractions were combined and concentrated at 30 °C in vacuo,
yielding 4.29t as a yellow foam/oil (75 mg, 50% yield). Rf = 0.72 in 10% MeOH in CH2Cl2. IR
(thin film, KBr) 3325 (br), 2980 (m), 1743 (w), 1711 (w), 1639 (s), 1521 (s), 1504 (s), 1441 (m),
1366 (w), 1124 (m), 1002 (w), 974 (m), 701 (m), 607 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ
7.24 (d, J = 3.5 Hz, 2H), 7.21 – 7.15 (m, 3H), 6.67 (s, 1H), 6.16 (d, J = 9.2 Hz, 1H), 4.92 (dd, J =
14.1, 8.2 Hz, 1H), 4.66 (td, J = 9.4, 4.2 Hz, 1H), 4.22 (dd, J = 7.2, 5.7 Hz, 1H), 3.71 (s, 3H), 3.67
– 3.54 (m, 2H), 3.17 (dd, J = 13.8, 5.6 Hz, 1H), 3.09 – 2.89 (m, 4H), 2.21 – 2.03 (m, 3H), 1.98 –
1.85 (m, 1H), 1.49 (s, 3H), 1.29 (s, 9H), 1.24 (s, 3H)..

13

C NMR (100 MHz, CDCl3) δ 173.9,

172.7, 170.8, 170.1, 155.3, 146.9 (m), 144.4 (m), 141.4 (m), 138.6 (m), 136.3, 136.1 (m), 129.3,
128.4, 126.9, 110.9 (t), 79.9, 61.4, 57.3, 52.9, 52.3, 51.5, 47.5, 38.2, 28.4, 27.9, 27.2, 25.3, 25.2,
23.6. HRMS (ESI+) m/z calculated for C33H40F5N4O7+: 699.2812. Found: 699.2852.

Boc-3Pal-DPro-Aib-Phe-OMe (4.29v).
Peptide S4.3 was synthesized as reported previously.S1 To a flask containing trimer S4.3 (50 mg,
0.13 mmol), HOBt H2O (28 mg, 0.21 mmol, 1.3 eq) and a stir bar was
added N-Boc-D-3-pyridylalanine (Boc-3Pal-OH; 41 mg, 0.15 mmol, 1.2
eq). The solid mixture was dissolved in dry CH2Cl2 (1.05 mL, 0.20 M
with respect to S4.3). EDC HCl (32 mg, 0.17 mmol, 1.3 eq) was then
added. The resulting solution was left to stir at RT as DIPEA (26 μL, 0.15 mmol, 1.2 eq with
respect to S4.3) was slowly added. The solution was allowed to stir for 20 hours before being
diluted with 20 mL CH2Cl2, poured into a separatory funnel, and washed with an equivalent
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volume of 10% aqueous (w/v) citric acid. The organic layer was separated and subsequently
washed with an equivalent volume each of saturated aqueous NaHCO3 and brine. Organic layers
were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced
pressure. Chromatography of the crude residue with dichloromethane/methanol was accomplished
on a Biotage Isolera Prime (SNAP 10g silica gel column, solvent gradient: 0% methanol in
dichloromethane (3 CV); 0-1% (3 CV), 1-2% (5 CV); 2-5% (10 CV); 5-10% (10 CV); 10% (3
CV); monitored at 210 and 254 nm). Product fractions were combined and concentrated at 30 °C
under reduced pressure, yielding 4.29v as a clear foam/oil (29 mg, 38% yield). 1H NMR (400
MHz, CDCl3) δ 8.51 – 8.44 (m, 1H), 8.44 – 8.40 (m, 1H), 7.55 – 7.49 (m, 1H), 7.23 – 7.17 (m,
1H), 7.12 (d, J = 6.5 Hz, 3H), 7.07 (d, J = 6.8 Hz, 3H), 6.90 (d, J = 7.2 Hz, 1H), 5.24 (d, J = 8.9
Hz, 1H), 4.80 (dd, J = 13.2, 6.1 Hz, 1H), 4.65 – 4.56 (m, 1H), 4.44 – 4.35 (m, 1H), 3.70 (s, 3H),
3.65 – 3.58 (m, 1H), 3.54 – 3.43 (m, 1H), 3.13 (ddd, J = 33.9, 13.9, 6.0 Hz, 2H), 2.92 (dd, J = 14.0,
5.0 Hz, 1H), 2.66 (dd, J = 14.0, 8.4 Hz, 1H), 2.29 – 2.18 (m, 1H), 1.96 – 1.83 (m, 3H), 1.51 (s,
3H), 1.39 (s, J = 3.2 Hz, 3H), 1.34 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 173.8, 172.5, 171.9,
170.4, 155.3, 150.9, 148.4, 137.2, 136.3, 132.3, 129.5, 129.3, 128.6, 128.5, 127.0, 123.5, 80.2,
60.9, 60.5, 57.3, 53.1, 52.4, 47.7, 37.7, 35.7, 28.4, 27.3, 26.5, 25.3, 24.5, 21.2, 14.3. HRMS (ESI+)
m/z calculated for C32H44N5O7+: 610.3236. Found: 610.3271.
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Note: Peptides 4.29i and 4.29j were synthesized by the Miller laboratory.
Characterization of Boc-Dmaa-DPro-[α-Me, D-Phe]-Leu-OMe (4.29i): White, foamy solid,
15% overall yield. Rf = 0.59 in 10% MeOH in CH2Cl2. 1H NMR (500
MHz, CDCl3): δ 7.34 (d, J = 8.6 Hz, 1H), 7.30 – 7.20 (m, 3H), 7.14 (d, J
= 7.0 Hz, 2H), 6.42 (s, 1H), 5.82 (d, J = 6.3 Hz, 1H), 4.75 – 4.62 (m, 1H),
4.44 (q, J = 6.9 Hz, 1H), 4.26 (dd, J = 7.6, 4.0 Hz, 1H), 3.87 – 3.79 (m,
1H), 3.72 (s, 3H), 3.66 – 3.58 (m, 1H), 3.56 (d, J = 13.7 Hz, 1H), 3.10 (d, J = 13.8 Hz, 1H), 2.63
(dd, J = 12.1, 7.6 Hz, 1H), 2.41 (dd, J = 12.2, 6.9 Hz, 1H), 2.27 (s, 6H), 2.25 – 2.18 (m, 1H), 2.13
– 2.01 (m, 2H), 2.01 – 1.87 (m, 2H), 1.77 – 1.60 (m, 4H), 1.41 (s, 9H), 1.38 (s, 3H), 0.98 – 0.85
(m, 6H). IR (thin film, KBr) 3324 (br), 2955 (br), 1748 (m), 1652 (s), 1522 (s), 1456 (m), 1367
(w), 1284 (w), 1163 (m), 860 (w), 708 (w) cm-1.

13

C NMR (150 MHz, CDCl3): δ 174.0, 173.6,

171.3, 170.4, 155.8, 137.1, 130.8, 127.9, 126.6, 79.9, 61.7, 60.2, 53.4, 51.9, 51.0, 50.8, 47.5, 45.6,
40.8, 40.2, 28.8, 28.4, 24.6, 24.1, 23.1, 21.7. HRMS (ESI+) m/z calculated for C32H52N5O7+:
618.3561. Found: 618.3452.

Characterization of Boc-Dmaa-DPro-[α-Me, L-Phe]-Leu-OMe (4.29j): White, foamy solid,
12% overall yield. 1H NMR (600 MHz, CDCl3): δ 7.26–7.24 (m, 2H),
7.24–7.21 (m, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.16–7.12 (m, 2H), 6.32 (s,
1H), 5.58 (s, 1H), 4.57 (ddd, J = 9.6, 7.8, 4.9 Hz, 1H), 4.33–4.30 (m, 1H),
4.28 (dd, J = 9.7, 4.2 Hz, 1H), 3.84–8.79 (m, 1H), 3.72–3.69 (m, 1H), 3.69
(s, 3H), 3.49 (q, J = 8.6 Hz, 1H), 3.09 (d, J = 13.8 Hz, 1H), 2.55–2.48 (m, 1H), 2.47–2.42 (m, 1H),
2.24 (s, 6H), 2.21–2.15 (m, H), 2.15–2.06 (m, 1H), 1.94–1.87 (m, 1H), 1.87–1.79 (m, 1H), 1.79–
1.70 (m, 2H), 1.63–1.57 (m, 1H), 1.41 (s, 3H), 1.38 (s, 9H), 0.94 (dd, J = 10.7, 6.5 Hz, 6H). 13C
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NMR (150 MHz, CDCl3): δ 173.9, 173.4, 171.2, 170.3, 155.7, 136.9, 130.8, 127.9, 126.5, 79.9,
61.6, 60.2, 59.6, 51.8, 50.9, 50.7, 47.4, 45.5, 40.7, 40.1, 28.8, 28.4, 24.5, 24.1, 23.0, 21.6. IR (thin
film, KBr) 3750 (br), 2955 (br), 2360 (w), 1748 (m), 1652 (s), 1540 (m), 1456 (m), 1367 (w),
1284 (w), 1163 (m), 860 (w), 708 (w) cm-1. HRMS (ESI+) m/z calculated for C32H52N5O7+:
618.3561. Found: 618.3867.

4.9.3. Peptide Screening Protocols and Optimization of Reaction Conditions: Halogenation of
4.27

2-Bromo-6-methoxy-4-methyl-7-oxo-3-(piperidine-1-carbonyl)cyclohepta-1,3,5-trien-1-yl
acetate (4.28a).
General Procedure. To an oven-dried 1-dram vial equipped with peptide catalyst 4.29d (1.84 mg,
0.003 mmol, 0.1 eq) was added troponoid 4.27 (8.3 mg, 0.300 mmol), a magnetic
stir bar, and CDCl3 (1.5 mL, 0.02 M). The solution was allowed to stir at ambient
temperature. N-Bromosuccinimide (NBS, 5.9 mg, 1.1 eq) was then added (all at
once) to the stirring solution at room temperature after the sides of the vial were wrapped in
aluminum foil. The reaction was further protected from light by turning off the lights in the
ventilation hood. Reaction progress was monitored by 1H-NMR in an NMR tube wrapped in
aluminum foil when not inside the NMR spectrometer. When the reaction reached full conversion
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of starting material (26 hours), it was quenched by addition of a flake of DMAP and 3 drops of
acetic anhydride and allowed to stir at ambient temperatures overnight. Acetylation progress was
monitored by thin layer chromatography. The solvent was removed under reduced pressure, and
the crude reaction mixture was purified by chromatography (Biotage Isolera Prime, 10 g silica gel
column, elution solvents: dichloromethane with 2% acetic acid additive, and acetone. Solvent
gradient: 0% acetone in dichloromethane (3 CV); 0-20% (10 CV); 20% (4 CV); 20-25% (8 CV);
25-30% (2 CV); 30-60% (5 CV)). Product fractions were concentrated to yield 4.28a as a yellow
oil (5.1 mg, 43% yield). Rf= 0.32 in 20% acetone in dichloromethane. IR (thin film, KBr) 3545
(br), 2938 (m), 2855 (m), 1770 (s), 1633 (s), 1591 (w), 1446 (w), 1298 (m), 1269 (s), 1223 (m),
1184 (w), 1135 (s), 1073 (m), 873 (w) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.73 (bs, 1H), 3.95 (s,
3H), 3.91 – 3.79 (m, 1H), 3.68 – 3.52 (m, 1H), 3.30 – 3.18 (m, 2H), 2.44 (s, 3H), 2.37 (s, 3H), 1.83
– 1.47 (m, 6H). 13C NMR (100 MHz, CDCl3; partial) δ 166.9, 137.2, 57.1, 47.3, 42.3, 26.4, 26.0,
25.2, 24.6, 20.8. HRMS (ESI+) m/z calculated for C17H21BrNO5+: 398.0598. Found: 398.0602.
HPLC 70:30 er (Chiralpak AS-H, 1.5 mL/min, 8% ethanol in hexanes, regulated at 40 °C, 254
nm). RT(major) = 22.8 min, RT(minor) = 25.6 min.
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Please see Table 4.1 in the main text for a summary of all peptides screened.

3-bromo-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1one (4.28).

General Procedure A. N-Bromosuccinimide (NBS, 1.1 equiv.) was added to a 0.02 M solution
of tropamide 4.27 (17.3 mg, 0.062 mmol, 1 equiv) and catalyst 4.29q (3.5 mg,
0.006 mmol, 0.1 equiv) in CDCl3 (3.12 mL) at 0 ºC (while shielded from light).
The reaction was allowed to stir for 72 hours. The reaction was then diluted with
4 mL of DCM, transferred to a separatory funnel, and quenched with an equivalent volume of a
pH 3 phosphate buffer (made by diluting 1.7 mL of 2.0 M aqueous sulfuric acid with 12 mL of 1.0
M pH 7 phosphate buffer), and extracted 3x. The combined organics were dried over sodium
sulfate, filtered, and concentrated under reduced pressure. Reversed phase chromatography of the
crude residue with water/acetonitrile was accomplished on a Biotage Isolera Prime (SNAP 12g
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C18 silica gel column, solvent gradient: 10% acetonitrile in water (3 CV); 10-23% (8 CV), 2335% (8 CV), 35-100% (6 CV); acetonitrile and water each contained 0.05% TFA). Product
fractions were combined, extracted with excess DCM (3x, Σ = 60 mL), filtered through Na2SO4
and concentrated at 30 °C in vacuo, yielding 4.28 as a waxy brown/yellow solid (11.2 mg, 50%
yield) with 1H-NMR data consistent with previously reported data. See Section 3.10.4 in Chapter
3 for characterization data. HPLC 75:25 er (Chiralpak IA, 1.5 mL/min, 35% acetonitrile in water
with 0.1% formic acid): RT(minor) = 7.2 min, RT(major) = 8.1 min.

General Procedure B. The same procedure as outlined above was followed, but the reaction was
run at ambient temperature. Such reactions were monitored for conversion by 1H-NMR. Upon
reaching full conversion, they were quenched according the procedure described above.

General Procedure C. The same procedure as outlined above (Procedure B), with Nchlorosuccinimide (NCS) used in place of N-bromosuccinimide (NBS). Additionally, the reaction

216

was instead quenched with a pH 3 phosphate buffer that was made by diluting 1.0 M phosphate
buffer with enough 2.0 M HCl solution to bring the total solution to a pH of 3.

General Procedure D. The same procedure as outlined above was followed (A and B only), but
the reaction was instead quenched with a pH 3 phosphate buffer that was made by diluting 1.0 M
phosphate buffer with enough 2.0 M HCl solution to bring the total solution to a pH of 3.

3-chloro-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1one (4.36).

Procedure

C.

To

a

solution

of

2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-

carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (8.0 mg, 0.029 mmol) and 4.29a (1.6
mg, 0.0029 mmol) in CDCl3 (1.44 mL, 0.02 M) was added N-chlorosuccinimide
(NCS, 4.2 mg, 0.032 mmol) at ambient temperature at which point the reaction
immediately turned red. The reaction was transferred to an oven-dried NMR tube for monitoring
the progress of the reaction and was also shielded from light. The reaction proved sluggish, and
NCS took 7 days to be fully consumed. After 9 days, 4.27 and 4.36 were present in a 1:0.78 ratio,
and conversion appeared to have plateaued. The reaction was then diluted with 4 mL of DCM,
transferred to a separatory funnel, and quenched with an equivalent volume of a pH 3 phosphate
buffer (made by diluting 10 mL of 1.0 M pH 7 phosphate buffer with 2.0 M HCl until a pH of 3
was reached), and extracted 3x. The combined organics were dried over sodium sulfate, filtered,
and concentrated under reduced pressure to yield a yellow oil. Reversed phase chromatography of
the crude residue with water/acetonitrile was accomplished on a Biotage Isolera Prime (SNAP 12g
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C18 silica gel column, solvent gradient: 10% acetonitrile in water (3 CV); 10-23% (8 CV), 2335% (8 CV), 35-100% (6 CV); acetonitrile and water each contained 0.05% TFA). Product
fractions were combined, extracted with excess DCM (3x, Σ = 50 mL), filtered through Na2SO4
and concentrated at 30 °C under reduced pressure to yield a yellow oil (1.0 mg, yield not
calculated). 1H NMR (400 MHz, CDCl3) δ 7.01 (s, 1H), 4.01 (s, 3H), 3.86 – 3.66 (m, 2H), 3.27 –
3.13 (m, 2H), 2.46 (s, 3H), 1.79 – 1.62 (m, 6H). 13C NMR (100 MHz, CDCl3; partial) δ 157.2,
121.5, 56.9, 47.2, 42.3, 26.1, 25.7, 25.3, 24.6. HR-LCMS (ESI+) m/z calculated for
C15H19ClNO4+: 312.0997. Found: 312.0999. HPLC 53:47 er (Chiralpak IC, 1.0 mL/min, 65%
acetonitrile in water with 0.1% formic acid, monitored at 265 nm). RT(minor) = 6.7 min, RT(major) =
10.2 min.
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Procedure

D.

To

a

solution

of

2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-

carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (11.2 mg, 0.040 mmol) and 4.29a
(2.18 mg, 0.004 mmol) in CDCl3 (2.02 mL, 0.02 M) was added
N-bromosuccinimide (NBS, 7.9 mg, 0.044 mmol) at 0 °C. The reaction was
transferred to an oven-dried NMR tube for monitoring the progress of the reaction
and shielded from light. After allowing the reaction to stir at 0 °C for 3 hours, the reaction was
then diluted with 4 mL of DCM, transferred to a separatory funnel, and quenched with an
equivalent volume of a pH 3 phosphate buffer (made by diluting 10 mL of 1.0 M pH 7 phosphate
buffer with 2.0 M HCl until a pH of 3 was reached), and extracted 3x. The combined organics
were dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield a
mixture of 4.28 and 4.36 in a 1:6 ratio by 1H-NMR. Reversed phase chromatography of the crude
residue with water/acetonitrile was accomplished on a Biotage Isolera Prime (SNAP 12g C18 silica

219

gel column, solvent gradient: 10% acetonitrile in water (3 CV); 10-23% (8 CV), 23-35% (8 CV),
35-100% (6 CV); acetonitrile and water each contained 0.05% TFA). Product fractions were
combined, extracted with excess DCM (3x, Σ = 60 mL), filtered through Na2SO4 and concentrated
at 30 °C under reduced pressure to yield a yellow oil (2.2 mg, 17% yield) with 1H-NMR data
consistent with previously reported data. HPLC 76:24 er (Chiralpak IC, 1.0 mL/min, 65%
acetonitrile in water with 0.1% formic acid, monitored at 265 nm). RT(minor) = 6.7 min, RT(major) =
10.2 min.

4.9.4. NMR Studies on Racemic and Uncatalyzed Conversion
Uncatalyzed Conversion. To a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (5.5 mg, 0.020 mmol) in CDCl3 (1.0 mL, 0.02 M)
was added N-bromosuccinimide (NBS, 3.9 mg, 0.022 mmol). The reaction was transferred to an
oven-dried NMR tube for monitoring the progress of the reaction and shielded from light. For
1

H-NMR spectra showing conversion, see Section 4.9.6.
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Racemic Conversion with 0.1 Equivalents of Base.
To an oven-dried 1-dram vial was added a solution of 2-hydroxy-7-methoxy-5-methyl-4(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1-one 4.27 (8.3 mg, 0.030 mmol) in CDCl3 (1.5 mL,
0.02 M) and N-bromosuccinimide (NBS, 5.9 mg, 0.033 mmol). The reaction was allowed to stir
at ambient temperature before adding triethylamine (0.4 μL, 0.003 mmol; added as a stock solution
in CDCl3). The reaction was transferred to an oven-dried NMR tube for monitoring the progress
of the reaction and shielded from light. 1H NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 7.03 (s, 1H),
6.99 (s, 1H), 4.00 (s, 3H), 3.96 (s, 3H), 3.89 – 3.54 (m, 4H), 3.25 – 3.17 (m, 4H), 2.43 (s, 3H),
2.41 (s, 3H), 1.80 – 1.41 (m, 12H). (1H-NMR of crude reaction. Triethylamine and succinimide
peak values omitted for clarity. For 1H-NMR spectrum, see Section 4.9.6.)

Racemic Conversion with Stoichiometric Base.

3-bromo-2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1one (4.28). In the presence of stoichiometric base, NBS was discovered to result in decomposition
of the reaction. Accordingly, brominating agent dibromodimethylhydantoin was used instead. To
a solution of 2-hydroxy-7-methoxy-5-methyl-4-(piperidine-1-carbonyl)cyclohepta-2,4,6-trien-1one 4.27 (10.8 mg, 0.039 mmol) in CDCl3 (1.30 mL) was added dibromodimethylhydantoiin
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(DBDMH, 14.25 mg, 0.05 mmol), followed by triethylamine (5.4 μL, 0.039 mmol). The reaction
was allowed to stir for 2 hours at rt before quenching with pH 3 phosphate buffer and extracting
with CH2Cl2. Combined organics were dried over Na2SO4, filtered, and concentrated under
reduced pressure to yield 4.28 as a pale yellow/brown waxy solid (5.6 mg, 88% yield) with 1HNMR data consistent with previously reported data. HPLC 51:49 er (Chiralpak IA, 1.5 mL/min,
35% acetonitrile in water with 0.1% formic acid). See Section 3.10.4 in Chapter 3 for
characterization data.
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4.9.5. NMR Studies on Intermediate 4.34

Synthesis and Tentative Characterization. To an oven-dried, 1-dram vial was added peptide
catalyst 4.29a (2.0 mg, 0.004 mmol, 20 mol%), troponoid 4.27 (5.2 mg, 0.019 mmol) in CDCl3
(0.937 mL, 0.02 M) and a magnetic stir bar. The solution was allowed to stir at ambient
temperature. N-Bromosuccinimide (NBS, 7.3 mg, 0.041 mmol, 2.2 eq) was then added (all at once)
to the stirring solution at room temperature after the sides of the vial were wrapped in aluminum
foil. The reaction was immediately transferred to an oven-dried NMR tube and wrapped in
aluminum foil. 1H NMR (400 MHz, CDCl3) δ 6.41 (q, J = 1.4 Hz, 1H), 3.63 (s, 3H), 3.62 (s, 1H),
2.12 (d, J = 1.3 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 180.1, 178.8, 177.4, 164.7, 135.2, 131.8,
57.6, 57.1, 46.6, 42.6, 28.4, 25.9, 25.3, 24.5. Not stable on LCMS, or long-lived enough to study
by HMBC or NOE correlation experiments. For 13C and HSQC data, see Section 4.9.6.

Base Quench Study.
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To an oven-dried, 1-dram vial was added peptide catalyst 4.29c (1.7 mg, 0.003 mmol),
troponoid 4.27 (8.7 mg, 0.031 mmol) in CDCl3 (1.56 mL, 0.02 M) and a magnetic stir bar. The
solution was allowed to stir at ambient temperature. N-Bromosuccinimide (NBS, 6.1 mg, 0.034
mmol) was then added (all at once) to the stirring solution at room temperature after the sides of
the vial were wrapped in aluminum foil. Reaction was monitored by 1H-NMR for 90 minutes to
ensure full conversion of starting material. At this time, all NBS was fully converted, and the
ratio of product 4.28 to intermediate 4.34 was 1:3.7.
Reaction 1 (top, blue): 4-Dimethylaminopyrydine (DMAP, 3.8 mg, 0.031 mmol) was
added. After 10 minutes, 1H-NMR showed total disappearance of intermediate 4.34. The ratio of
starting material 4.27 to product 4.28 was 2:3.
Reaction 2 (bottom, red): Triethylamine (4.4 μL, 0.031 mmol) was added. After 10
minutes, 1H-NMR showed total disappearance of intermediate 4.34. The ratio of starting material
4.27 to product 4.28 was 3:2.

Halogenation Exchange Study. Refer to Section 4.9.3, General Procedure C. These results are
summarized in full in the main text.
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4.9.6. NMR Spectra of New Compounds
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